Publications: Prof Thomas Powles

Sonpavde G, Manitz J, Gao C, Tayama D, Kaiser C, Hennessy D, Makari D, Gupta A et al. ( 2020 ) . Five-Factor Prognostic Model for Survival of Post-Platinum Patients with Metastatic Urothelial Carcinoma Receiving PD-L1 Inhibitors . The Journal of urology vol. 204 , ( 6 ) 1173 - 1179 .

Loveday C, Litchfield K, Proszek PZ, Cornish AJ, Santo F, Levy M, Macintyre G, Holryod A et al. ( 2020 ) . Genomic landscape of platinum resistant and sensitive testicular cancers . Nature Communications vol. 11 , ( 1 )

Necchi A, Nishiyama H, Matsubara N, Lee JL, Petrylak DP, de Wit R, Drakaki A, Liepa AM et al. ( 2020 ) . Health-related quality of life in the randomized phase 3 study of ramucirumab plus docetaxel versus placebo plus docetaxel in platinum-refractory advanced urothelial carcinoma (RANGE) . BMC Urology vol. 20 , ( 1 )

Albiges L, Tannir N, Burotto M, Mcdermott D, Plimack E, Barthélémy P, Porta C, Powles T et al. ( 2020 ) . Nivolumab + ipilimumab (N+I) vs sunitinib (S) dans le traitement de première ligne du carcinome rénal avancé (aRCC) dans l’étude CheckMate 214 : suivi à 4 ans et analyse en sous-groupe des patients (pts) non néphrectomisés . Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie vol. 30 , ( 13 ) 785 - 786 .

Wallis CJD, Catto JWF, Finelli A, Glaser AW, Gore JL, Loeb S, Morgan TM, Morgans AK et al. ( 2020 ) . The Impact of the COVID-19 Pandemic on Genitourinary Cancer Care: Re-envisioning the Future . European Urology vol. 78 , ( 5 ) 731 - 742 .

Lee LYW, Cazier JB, Starkey T, Briggs SEW, Arnold R, Bisht V, Booth S, Campton NA et al. ( 2020 ) . COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study . The Lancet Oncology vol. 21 , ( 10 ) 1309 - 1316 .

Martinez Chanza N, Werner L, Plimack E, Yu EY, Alva AS, Crabb SJ, Powles T, Rosenberg JE et al. ( 2020 ) . Incidence, Patterns, and Outcomes with Adjuvant Chemotherapy for Residual Disease After Neoadjuvant Chemotherapy in Muscle-invasive Urinary Tract Cancers . European urology oncology vol. 3 , ( 5 ) 671 - 679 .

Powles T, Park SH, Voog E, Caserta C, Valderrama BP, Gurney H, Kalofonos H, Radulovi¿ S et al. ( 2020 ) . Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma . New England Journal of Medicine vol. 383 , ( 13 ) 1218 - 1230 .

Grünwald V, Voss MH, Rini BI, Powles T, Albiges L, Giles RH, Jonasch E ( 2020 ) . Axitinib plus immune checkpoint inhibitor: evidence- and expert-based consensus recommendation for treatment optimisation and management of related adverse events . British Journal of Cancer vol. 123 , ( 6 ) 898 - 904 .

Hall PE, Shepherd STC, Brown J, Larkin J, Jones R, Ralph C, Hawkins R, Chowdhury S et al. ( 2020 ) . Radiological Response Heterogeneity Is of Prognostic Significance in Metastatic Renal Cell Carcinoma Treated with Vascular Endothelial Growth Factor-targeted Therapy . European Urology Focus vol. 6 , ( 5 ) 999 - 1005 .

Tannir NM, Signoretti S, Choueiri TK, McDermott DF, Motzer RJ, Flaifel A, Pignon J-C, Ficial M et al. ( 2020 ) . Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma . Clin Cancer Res

Vuky J, Balar AV, Castellano D, O¿Donnell PH, Grivas P, Bellmunt J, Powles T, Bajorin D et al. ( 2020 ) . Long-term outcomes in KEYNOTE-052: Phase II study investigating first-line pembrolizumab in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer . Journal of Clinical Oncology vol. 38 , ( 23 ) 2658 - 2666 .

Szabados B, Abu-Ghanem Y, Grant M, Choy J, Bex A, Powles T ( 2020 ) . Clinical Characteristics and Outcome for Four SARS-CoV-2-infected Cancer Patients Treated with Immune Checkpoint Inhibitors . European Urology vol. 78 , ( 2 ) 276 - 280 .

Abu-Ghanem Y, Fernández-Pello S, Bex A, Ljungberg B, Albiges L, Dabestani S, Giles RH, Hofmann F et al. ( 2020 ) . Limitations of Available Studies Prevent Reliable Comparison Between Tumour Ablation and Partial Nephrectomy for Patients with Localised Renal Masses: A Systematic Review from the European Association of Urology Renal Cell Cancer Guideline Panel . European urology oncology vol. 3 , ( 4 ) 433 - 452 .

Motzer RJ, Escudier B, McDermott DF, Arén Frontera O, Melichar B, Powles T, Donskov F, Plimack ER et al. ( 2020 ) . Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial . Journal for ImmunoTherapy of Cancer vol. 8 , ( 2 )

Witjes JA, Babjuk M, Bellmunt J, Bruins HM, De Reijke TM, De Santis M, Gillessen S, James N et al. ( 2020 ) . Corrigendum to ‘EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer—An International Collaborative Multistakeholder Effort Under the Auspices of the EAU-ESMO Guidelines Committees’ [European Urology 77 (2020) 223–250](S0302283819307638)(10.1016/j.eururo.2019.09.035) . European Urology vol. 78 , ( 1 ) e48 - e50 .

Pal SK, McDermott DF, Atkins MB, Escudier B, Rini BI, Motzer RJ, Fong L, Joseph RW et al. ( 2020 ) . Patient-reported outcomes in a phase 2 study comparing atezolizumab alone or with bevacizumab vs sunitinib in previously untreated metastatic renal cell carcinoma . BJU International vol. 126 , ( 1 ) 73 - 82 .

Wallis CJD, Novara G, Marandino L, Bex A, Kamat AM, Karnes RJ, Morgan TM, Mottet N et al. ( 2020 ) . Risks from Deferring Treatment for Genitourinary Cancers: A Collaborative Review to Aid Triage and Management During the COVID-19 Pandemic[Formula presented] . European Urology vol. 78 , ( 1 ) 29 - 42 .

Lee LYW, Cazier JB, Angelis V, Arnold R, Bisht V, Campton NA, Chackathayil J, Cheng VWT et al. ( 2020 ) . COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: A prospective cohort study . The Lancet vol. 395 , ( 10241 ) 1919 - 1926 .

Powles T, Park SH, Voog E, Caserta C, Valderrama BP, Gurney H, Kalofonos H, Radulovic S et al. ( 2020 ) . Maintenance avelumab + best supportive care (BSC) versus BSC alone after platinum-based first-line (1L) chemotherapy in advanced urothelial carcinoma (UC): JAVELIN Bladder 100 phase III interim analysis . Journal of Clinical Oncology vol. 38 , ( 18_suppl ) lba1 - lba1 .

Khan Z, Di Nucci F, Kwan A, Hammer C, Mariathasan S, Rouilly V, Carroll J, Fontes M et al. ( 2020 ) . Polygenic risk for skin autoimmunity impacts immune checkpoint blockade in bladder cancer . Proceedings of the National Academy of Sciences of the United States of America vol. 117 , ( 22 ) 12288 - 12294 .

Gillessen S, Powles T ( 2020 ) . Advice Regarding Systemic Therapy in Patients with Urological Cancers During the COVID-19 Pandemic . European Urology vol. 77 , ( 6 ) 667 - 668 .

Atkins MB, Rini BI, Motzer RJ, Powles T, McDermott DF, Suarez C, Bracarda S, Stadler WM et al. ( 2020 ) . Patient-Reported Outcomes from the Phase III Randomized IMmotion151 Trial: Atezolizumab þ Bevacizumab versus Sunitinib in Treatment-Naïve Metastatic Renal Cell Carcinoma . Clinical Cancer Research vol. 26 , ( 11 ) 2506 - 2514 .

Grivas P, Plimack ER, Balar AV, Castellano D, O'Donnell PH, Bellmunt J, Powles T, Hahn NM et al. ( 2020 ) . Pembrolizumab as First-line Therapy in Cisplatin-ineligible Advanced Urothelial Cancer (KEYNOTE-052): Outcomes in Older Patients by Age and Performance Status . European urology oncology vol. 3 , ( 3 ) 351 - 359 .

Powles T, Kockx M, Rodriguez-Vida A, Duran I, Crabb SJ, Van Der Heijden MS, Szabados B, Pous AF et al. ( 2020 ) . Publisher Correction: Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial (Nature Medicine, (2019), 25, 11, (1706-1714), 10.1038/s41591-019-0628-7) . Nature Medicine vol. 26 , ( 6 )

Szabados B, Powles T ( 2020 ) . Immune checkpoint inhibition in urothelial carcinoma . The Lancet vol. 395 , ( 10236 ) 1522 - 1523 .

Yuen KC, Liu LF, Gupta V, Madireddi S, Keerthivasan S, Li C, Rishipathak D, Williams P et al. ( 2020 ) . High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockade . Nature Medicine vol. 26 , ( 5 ) 693 - 698 .

Fulton B, Jones R, Powles T, Crabb S, Paul J, Birtle A, Chowdhury S, Hussain S et al. ( 2020 ) . ATLANTIS: A randomised multi-arm phase II biomarker-directed umbrella screening trial of maintenance targeted therapy after chemotherapy in patients with advanced or metastatic urothelial cancer . Trials vol. 21 , ( 1 )

Birtle A, Johnson M, Chester J, Jones R, Dolling D, Bryan RT, Harris C, Winterbottom A et al. ( 2020 ) . Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trial . The Lancet vol. 395 , ( 10232 ) 1268 - 1277 .

Kamoun A, de Reyniès A, Allory Y, Sjödahl G, Robertson AG, Seiler R, Hoadley KA, Groeneveld CS et al. ( 2020 ) . A Consensus Molecular Classification of Muscle-invasive Bladder Cancer[Formula presented] . European Urology vol. 77 , ( 4 ) 420 - 433 .

de Bruijn R, Wimalasingham A, Szabados B, Stewart GD, Welsh SJ, Kuusk T, Blank C, Haanen J et al. ( 2020 ) . Deferred Cytoreductive Nephrectomy Following Presurgical Vascular Endothelial Growth Factor Receptor-targeted Therapy in Patients with Primary Metastatic Clear Cell Renal Cell Carcinoma: A Pooled Analysis of Prospective Trial Data . European urology oncology vol. 3 , ( 2 ) 168 - 173 .

Chalabi M, Cardona A, Nagarkar DR, Dhawahir Scala A, Gandara DR, Rittmeyer A, Albert ML, Powles T et al. ( 2020 ) . Efficacy of chemotherapy and atezolizumab in patients with non-small-cell lung cancer receiving antibiotics and proton pump inhibitors: pooled post hoc analyses of the OAK and POPLAR trials . Annals of Oncology vol. 31 , ( 4 ) 525 - 531 .

Kamoun A, de Reyniès A, Allory Y, Sjödahl G, Robertson AG, Seiler R, Hoadley KA, Groeneveld CS et al. ( 2020 ) . Reply To Kenneth B. Yatai, Mark J. Dunning, Dennis Wang. Consensus Genomic Subtypes of Muscle-invasive Bladder Cancer: A Step in the Right Direction but Still a Long Way To Go. Eur Urol 2020;77:434–5 . European Urology vol. 77 , ( 4 ) 436 - 438 .

Al-Lamki RS, Hudson NJ, Bradley JR, Warren AY, Eisen T, Welsh SJ, Riddick ACP, O`Mahony FC et al. ( 2020 ) . The efficacy of sunitinib treatment of renal cancer cells is associated with the Protein PHAX in vitro . Biology vol. 9 , ( 4 )

Powles T ( 2020 ) . Treatment Choices for Front-line Metastatic Clear Cell Renal Cancer . European Urology vol. 77 , ( 4 ) 454 - 456 .

Gómez de Liaño Lista A, van Dijk N, de Velasco Oria de Rueda G, Necchi A, Lavaud P, Morales-Barrera R, Alonso Gordoa T, Maroto P et al. ( 2020 ) . Clinical outcome after progressing to frontline and second-line Anti–PD-1/PD-L1 in advanced urothelial cancer[Formula presented] . European Urology vol. 77 , ( 2 ) 269 - 276 .

Witjes JA, Babjuk M, Bellmunt J, Maxim Bruins H, De Reijke TM, De Santis M, Gillessen S, James N et al. ( 2020 ) . EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer—An International Collaborative Multistakeholder Effort^†[Formula presented]: Under the Auspices of the EAU-ESMO Guidelines Committees . European Urology vol. 77 , ( 2 ) 223 - 250 .

Fernández-Pello S, Hora M, Kuusk T, Tahbaz R, Dabestani S, Abu-Ghanem Y, Albiges L, Giles RH et al. ( 2020 ) . Management of Sporadic Renal Angiomyolipomas: A Systematic Review of Available Evidence to Guide Recommendations from the European Association of Urology Renal Cell Carcinoma Guidelines Panel . European urology oncology vol. 3 , ( 1 ) 57 - 72 .

Donskov F, Motzer RJ, Voog E, Hovey E, Grüllich C, Nott LM, Cuff K, Gil T et al. ( 2020 ) . Outcomes based on age in the phase III METEOR trial of cabozantinib versus everolimus in patients with advanced renal cell carcinoma . European Journal of Cancer vol. 126 , 1 - 10 .

Rini BI, Motzer RJ, Powles T, McDermott DF, Escudier B, Donskov F, Hawkins R, Bracarda S et al. ( 2020 ) . Atezolizumab plus Bevacizumab Versus Sunitinib for Patients with Untreated Metastatic Renal Cell Carcinoma and Sarcomatoid Features: A Prespecified Subgroup Analysis of the IMmotion151 Clinical Trial . European Urology

Motzer RJ, Robbins PB, Powles T, Albiges L, Haanen JB, Larkin J, Mu XJ, Ching KA et al. ( 2020 ) . Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial . Nature Medicine

Liu WK, Lam JM, Butters T, Grant M, Jackson-Spence F, Bex A, Powles T, Szabados B ( 2020 ) . Cytoreductive nephrectomy in metastatic renal cell carcinoma: outcome of patients treated with a multidisciplinary, algorithm-driven approach . World Journal of Urology

Grant M, Szabados B, Kuusk T, Powles T, Bex A ( 2020 ) . Cytoreductive nephrectomy: Does CARMENA (Cancer du Rein Metastatique Nephrectomie et Antiangiogéniques) change everything? . Current Opinion in Urology vol. 30 , ( 1 ) 36 - 40 .

Drakaki A, Kirby CJ, Van Der Heijden MS, Petrylak DP, Powles T, Chi KN, Fléchon A, Necchi A et al. ( 2020 ) . Docetaxel with or without Ramucirumab after Platinum-Based Chemotherapy and Checkpoint Inhibitors in Advanced Urothelial Carcinoma: A Pre-Specified Subgroup Analysis from the Phase 3 RANGE Trial . Bladder Cancer vol. 6 , ( 1 ) 43 - 52 .

Powles T, van der Heijden MS, Castellano D, Galsky MD, Loriot Y, Petrylak DP, Ogawa O, Park SH et al. ( 2020 ) . Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial . The Lancet Oncology

Grunewald CM, Henn A, Galsky MD, Plimack ER, Harshman LC, Yu EY, Crabb SJ, Pal SK et al. ( 2020 ) . Impact of timing of adjuvant chemotherapy following radical cystectomy for bladder cancer on patient survival . Urologic Oncology: Seminars and Original Investigations

Leow JJ, Chong YL, Chang SL, Valderrama BP, Powles T, Bellmunt J ( 2020 ) . Neoadjuvant and Adjuvant Chemotherapy for Upper Tract Urothelial Carcinoma: A 2020 Systematic Review and Meta-analysis, and Future Perspectives on Systemic Therapy . European Urology

Petrylak DP, de Wit R, Chi KN, Drakaki A, Sternberg CN, Nishiyama H, Castellano D, Hussain SA et al. ( 2020 ) . Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial . The Lancet Oncology vol. 21 , ( 1 ) 105 - 120 .

Leow JJ, Chong YL, Chang SL, Valderrama BP, Powles T, Bellmunt J ( 2020 ) . Reply to Alexander Andreev-Drakhlin, Jianjun Gao, Arlene Siefker-Radtke. Levelling the Evidence: A Comparison of Neoadjuvant and Adjuvant Treatment for Upper Tract Urothelial Carcinoma. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.08.033 . European Urology

Powles T, Walker J, Andrew Williams J, Bellmunt J ( 2020 ) . The evolving role of PD-L1 testing in patients with metastatic urothelial carcinoma . Cancer Treatment Reviews vol. 82 ,

Buckley HL, Collinson FJ, Ainsworth G, Poad H, Flanagan L, Katona E, Howard HC, Murden G et al. ( 2019 ) . PRISM protocol: a randomised phase II trial of nivolumab in combination with alternatively scheduled ipilimumab in first-line treatment of patients with advanced or metastatic renal cell carcinoma . BMC Cancer . vol. 19 ,

Powles T, Kockx M, Rodriguez-Vida A, Duran I, Crabb SJ, Van Der Heijden MS, Szabados B, Pous AF et al. ( 2019 ) . Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial . Nature Medicine vol. 25 , ( 11 ) 1706 - 1714 .

Horwich A, Babjuk M, Bellmunt J, Bruins HM, De Reijke TM, De Santis M, Gillessen S, James N et al. ( 2019 ) . EAU–ESMO consensus statements on the management of advanced and variant bladder cancer—an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees . Annals of Oncology vol. 30 , ( 11 ) 1697 - 1727 .

Bamias A, Tzannis K, Harshman LC, Crabb SJ, Wong YN, Kumar Pal S, De Giorgi U, Ladoire S et al. ( 2019 ) . Erratum: Impact of contemporary patterns of chemotherapy utilization on survival in patients with advanced cancer of the urinary tract: a Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC) (Annals of Oncology (2018) 29(2) (361–369), (S0923753419350392), (10.1093/annonc/mdx692)) . Annals of Oncology vol. 30 , ( 11 )

Flaifel A, Xie W, Braun DA, Ficial M, Bakouny Z, Nassar AH, Jennings RB, Escudier B et al. ( 2019 ) . PD-L1 expression and clinical outcomes to cabozantinib, everolimus, and sunitinib in patients with metastatic renal cell carcinoma: Analysis of the randomized clinical trials Meteor and Cabosun . Clinical Cancer Research vol. 25 , ( 20 ) 6080 - 6088 .

Song D, Powles T, Shi L, Zhang L, Ingersoll MA, Lu YJ ( 2019 ) . Bladder cancer, a unique model to understand cancer immunity and develop immunotherapy approaches . Journal of Pathology vol. 249 , ( 2 ) 151 - 165 .

Motzer RJ, Rini BI, McDermott DF, Arén Frontera O, Hammers HJ, Carducci MA, Salman P, Escudier B et al. ( 2019 ) . Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial . The Lancet Oncology vol. 20 , ( 10 ) 1370 - 1385 .

Szabados B, van Dijk N, Tang YZ, van der Heijden MS, Wimalasingham A, Gomez de Liano A, Chowdhury S, Hughes S et al. ( 2019 ) . Re: Response rate to chemotherapy after immune checkpoint inhibition in metastatic urothelial cancer . Journal of Urology vol. 202 , ( 4 ) 658 - 659 .

De Bruijn RE, Mulders P, Jewett MA, Wagstaff J, Van Thienen JV, Blank CU, Van Velthoven R, Wood L et al. ( 2019 ) . Surgical Safety of Cytoreductive Nephrectomy Following Sunitinib: Results from the Multicentre, Randomised Controlled Trial of Immediate Versus Deferred Nephrectomy (SURTIME)(Figure presented.) . European Urology vol. 76 , ( 4 ) 437 - 440 .

Bamias A, Tzannis K, Bamia C, Harshman LC, Crabb S, Plimack ER, Pal S, De Giorgi U et al. ( 2019 ) . The Impact of Cisplatin- or Non-Cisplatin-Containing Chemotherapy on Long-Term and Conditional Survival of Patients with Advanced Urinary Tract Cancer . Oncologist vol. 24 , ( 10 ) 1348 - 1355 .

Martini A, Jia R, Ferket BS, Waingankar N, Plimack ER, Crabb SJ, Harshman LC, Yu EY et al. ( 2019 ) . Tumor downstaging as an intermediate endpoint to assess the activity of neoadjuvant systemic therapy in patients with muscle-invasive bladder cancer . Cancer vol. 125 , ( 18 ) 3155 - 3163 .

Michaelson MD, Gupta S, Agarwal N, Szmulewitz R, Powles T, Pili R, Bruce JY, Vaishampayan U et al. ( 2019 ) . A Phase Ib Study of Axitinib in Combination with Crizotinib in Patients with Metastatic Renal Cell Cancer or Other Advanced Solid Tumors . Oncologist vol. 24 , ( 9 ) 1151 - e817 .

Auvray M, Auclin E, Barthelemy P, Bono P, Kellokumpu-Lehtinen P, Gross-Goupil M, De Velasco G, Powles T et al. ( 2019 ) . Erratum to ‘Second-line targeted therapies after nivolumab-ipilimumab failure in metastatic renal cell carcinoma’ (European Journal of Cancer (2019) 108 (33–40), (S0959804918315399), (10.1016/j.ejca.2018.11.031)) . European Journal of Cancer vol. 119 , 200 - 201 .

Dabestani S, Beisland C, Stewart GD, Bensalah K, Gudmundsson E, Lam TB, Gietzmann W, Zakikhani P et al. ( 2019 ) . Intensive Imaging-Based Follow-up of Surgically Treated Localised Renal Cell Carcinoma Does Not Improve Post-Recurrence Survival: Results from a European Multicentre Database (RECUR) . Journal of Urology vol. 202 , ( 3 ) 455 - 456 .

Dabestani S, Beisland C, Stewart GD, Bensalah K, Gudmundsson E, Lam TB, Gietzmann W, Zakikhani P et al. ( 2019 ) . Long-term Outcomes of Follow-up for Initially Localised Clear Cell Renal Cell Carcinoma: RECUR Database Analysis . European Urology Focus vol. 5 , ( 5 ) 857 - 866 .

Grimm MO, Bex A, De Santis M, Ljungberg B, Catto JWF, Rouprêt M, Hussain SA, Bellmunt J et al. ( 2019 ) . Safe Use of Immune Checkpoint Inhibitors in the Multidisciplinary Management of Urological Cancer: The European Association of Urology Position in 2019 . European Urology vol. 76 , ( 3 ) 368 - 380 .

Alifrangis C, McGovern U, Freeman A, Powles T, Linch M ( 2019 ) . Molecular and histopathology directed therapy for advanced bladder cancer . Nature Reviews Urology vol. 16 , ( 8 ) 465 - 483 .

Albiges L, Powles T, Staehler M, Bensalah K, Giles RH, Hora M, Kuczyk MA, Lam TB et al. ( 2019 ) . Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibition Is the New Backbone in First-line Treatment of Metastatic Clear-cell Renal Cell Carcinoma . European Urology vol. 76 , ( 2 ) 151 - 156 .

Woolston A, Khan K, Spain G, Barber LJ, Griffiths B, Gonzalez-Exposito R, Hornsteiner L, Punta M et al. ( 2019 ) . Genomic and Transcriptomic Determinants of Therapy Resistance and Immune Landscape Evolution during Anti-EGFR Treatment in Colorectal Cancer . Cancer Cell vol. 36 , ( 1 ) 35 - 50.e9 .

Neves JB, Shepherd S, Cullen D, Powles T, Aitchison M, Tran MGB ( 2019 ) . Performance and cost of a renal cancer specialist multidisciplinary team meeting: Results from 1500 discussions . Journal of Clinical Urology vol. 12 , ( 4 ) 314 - 319 .

Sternberg CN, Loriot Y, James N, Choy E, Castellano D, Lopez-Rios F, Banna GL, De Giorgi U et al. ( 2019 ) . Primary Results from SAUL, a Multinational Single-arm Safety Study of Atezolizumab Therapy for Locally Advanced or Metastatic Urothelial or Nonurothelial Carcinoma of the Urinary Tract . European Urology vol. 76 , ( 1 ) 73 - 81 .

Porta C, Cosmai L, Leibovich BC, Powles T, Gallieni M, Bex A ( 2019 ) . The adjuvant treatment of kidney cancer: a multidisciplinary outlook . Nature Reviews Nephrology vol. 15 , ( 7 ) 423 - 433 .

Rini BI, Powles T ( 2019 ) . Immune Checkpoint Blockade plus Axitinib for Renal-Cell Carcinoma. Reply . The New England journal of medicine vol. 380 , ( 26 )

Rini BI, Powles T, Atkins MB, Escudier B, McDermott DF, Suarez C, Bracarda S, Stadler WM et al. ( 2019 ) . Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial . The Lancet vol. 393 , ( 10189 ) 2404 - 2415 .

Ljungberg B, Albiges L, Abu-Ghanem Y, Bensalah K, Dabestani S, Montes SFP, Giles RH, Hofmann F et al. ( 2019 ) . European Association of Urology Guidelines on Renal Cell Carcinoma: The 2019 Update . European Urology vol. 75 , ( 5 ) 799 - 810 .

Gonzalez-Exposito R, Semiannikova M, Griffiths B, Khan K, Barber LJ, Woolston A, Spain G, Von Loga K et al. ( 2019 ) . CEA expression heterogeneity and plasticity confer resistance to the CEA-targeting bispecific immunotherapy antibody cibisatamab (CEA-TCB) in patient-derived colorectal cancer organoids . Journal for ImmunoTherapy of Cancer vol. 7 , ( 1 )

Lam JM, Liu WK, Powles T, Tang YZ, Szabados B ( 2019 ) . Single-centre Experience of Patients with Metastatic Urothelial Cancer Treated with Chemotherapy Following Immune Checkpoint Inhibition . Eur Urol Oncol

Vogel C, Ziegelmüller B, Ljungberg B, Bensalah K, Bex A, Canfield S, Giles RH, Hora M et al. ( 2019 ) . Imaging in Suspected Renal-Cell Carcinoma: Systematic Review . Clinical Genitourinary Cancer vol. 17 , ( 2 ) e345 - e355 .

Rini BI, Plimack ER, Stus V, Gafanov R, Hawkins R, Nosov D, Pouliot F, Alekseev B et al. ( 2019 ) . Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma . New England Journal of Medicine vol. 380 , ( 12 ) 1116 - 1127 .

Perez-Gracia JL, Loriot Y, Rosenberg JE, Powles T, Necchi A, Hussain SA, Morales-Barrera R, Retz MM et al. ( 2019 ) . Corrigendum re: “Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Outcomes by Prior Number of Regimens” (European Urology (2018) 73(3) (462–468), (S0302283817310151) (10.1016/j.eururo.2017.11.023)) . European Urology vol. 75 , ( 3 ) e82 - e83 .

Necchi A, Mariani L, Lo Vullo S, Yu EY, Woods ME, Wong YN, Harshman LC, Alva A et al. ( 2019 ) . Lack of Effectiveness of Postchemotherapy Lymphadenectomy in Bladder Cancer Patients with Clinical Evidence of Metastatic Pelvic or Retroperitoneal Lymph Nodes Only: A Propensity Score-based Analysis . European Urology Focus vol. 5 , ( 2 ) 242 - 249 .

Grünwald V, Powles T, Choueiri TK, Hutson TE, Porta C, Eto M, Sternberg CN, Rha SY et al. ( 2019 ) . Lenvatinib plus everolimus or pembrolizumab versus sunitinib in advanced renal cell carcinoma: Study design and rationale . Future Oncology vol. 15 , ( 9 ) 929 - 941 .

van Dijk N, Funt SA, Blank CU, Powles T, Rosenberg JE, van der Heijden MS ( 2019 ) . The Cancer Immunogram as a Framework for Personalized Immunotherapy in Urothelial Cancer . European Urology vol. 75 , ( 3 ) 435 - 444 .

Bex A, Mulders P, Jewett M, Wagstaff J, Van Thienen JV, Blank CU, Van Velthoven R, Del Pilar Laguna M et al. ( 2019 ) . Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients with Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib: The SURTIME Randomized Clinical Trial . JAMA Oncology vol. 5 , ( 2 ) 164 - 170 .

Auvray M, Auclin E, Barthelemy P, Bono P, Kellokumpu-Lehtinen P, Gross-Goupil M, De Velasco G, Powles T et al. ( 2019 ) . Second-line targeted therapies after nivolumab-ipilimumab failure in metastatic renal cell carcinoma . European Journal of Cancer vol. 108 , 33 - 40 .

Merseburger AS, Apolo AB, Chowdhury S, Hahn NM, Galsky MD, Milowsky MI, Petrylak D, Powles T et al. ( 2019 ) . SIU-ICUD recommendations on bladder cancer: systemic therapy for metastatic bladder cancer . World Journal of Urology vol. 37 , ( 1 ) 95 - 105 .

Kuusk T, Szabados B, Liu WK, Powles T, Bex A ( 2019 ) . Cytoreductive nephrectomy in the current treatment algorithm . Therapeutic Advances in Medical Oncology vol. 11 ,

Dabestani S, Beisland C, Stewart GD, Bensalah K, Gudmundsson E, Lam TB, Gietzmann W, Zakikhani P et al. ( 2019 ) . Increased use of cross-sectional imaging for follow-up does not improve post-recurrence survival of surgically treated initially localized R.C.C.: results from a European multicenter database (R.E.C.U.R.) . Scandinavian Journal of Urology vol. 53 , ( 1 ) 14 - 20 .

de Velasco G, Bex A, Albiges L, Powles T, Rini BI, Motzer RJ, Heng DYC, Escudier B ( 2019 ) . Sequencing and Combination of Systemic Therapy in Metastatic Renal Cell Carcinoma . European Urology Oncology

Bhindi B, Abel EJ, Albiges L, Bensalah K, Boorjian SA, Daneshmand S, Karam JA, Mason RJ et al. ( 2019 ) . Systematic Review of the Role of Cytoreductive Nephrectomy in the Targeted Therapy Era and Beyond: An Individualized Approach to Metastatic Renal Cell Carcinoma . European Urology vol. 75 , ( 1 ) 111 - 128 .

Lalani AKA, McGregor BA, Albiges L, Choueiri TK, Motzer R, Powles T, Wood C, Bex A ( 2019 ) . Systemic Treatment of Metastatic Clear Cell Renal Cell Carcinoma in 2018: Current Paradigms, Use of Immunotherapy, and Future Directions . European Urology vol. 75 , ( 1 ) 100 - 110 .

Powles T, Rini B ( 2018 ) . Novel agents and drug development needs in advanced clear cell renal cancer . Journal of Clinical Oncology vol. 36 , ( 36 ) 3639 - 3644 .

Bex A, Albiges L, Staehler M, Bensalah K, Giles RH, Dabestani S, Hofmann F, Hora M et al. ( 2018 ) . A Joint Statement from the European Association of Urology Renal Cell Cancer Guidelines Panel and the International Kidney Cancer Coalition: The Rejection of Ipilimumab and Nivolumab for Renal Cancer by the Committee for Medicinal Products for Human Use Does not Change Evidence-based Guideline Recommendations . European Urology vol. 74 , ( 6 ) 849 - 851 .

McDermott DF, Huseni MA, Atkins MB, Motzer RJ, Rini BI, Escudier B, Fong L, Joseph RW et al. ( 2018 ) . Erratum to: Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma (Nature Medicine, (2018), 24, 6, (749-757), 10.1038/s41591-018-0053-3) . Nature Medicine vol. 24 , ( 12 )

Sonpavde GP, Mariani L, Lo Vullo S, Raggi D, Giannatempo P, Bamias A, Crabb SJ, Bellmunt J et al. ( 2018 ) . Impact of the Number of Cycles of Platinum Based First Line Chemotherapy for Advanced Urothelial Carcinoma . Journal of Urology vol. 200 , ( 6 ) 1207 - 1214 .

Necchi A, Pond GR, Smaldone MC, Pal SK, Chan K, Wong YN, Viterbo R, Sonpavde G et al. ( 2018 ) . Robot-assisted Versus Open Radical Cystectomy in Patients Receiving Perioperative Chemotherapy for Muscle-invasive Bladder Cancer: The Oncologist's Perspective from a Multicentre Study . European Urology Focus vol. 4 , ( 6 ) 937 - 945 .

Bex A, Albiges L, Ljungberg B, Bensalah K, Dabestani S, Giles RH, Hofmann F, Hora M et al. ( 2018 ) . Updated European Association of Urology Guidelines for Cytoreductive Nephrectomy in Patients with Synchronous Metastatic Clear-cell Renal Cell Carcinoma . European Urology vol. 74 , ( 6 ) 805 - 809 .

Bex A, Powles T, Haanen J ( 2018 ) . To the editor . New England Journal of Medicine vol. 379 , ( 19 ) 1877 - 1878 .

Sun M, Marconi L, Eisen T, Escudier B, Giles RH, Haas NB, Harshman LC, Quinn DI et al. ( 2018 ) . Adjuvant Vascular Endothelial Growth Factor–targeted Therapy in Renal Cell Carcinoma: A Systematic Review and Pooled Analysis [Figure presented] . European Urology vol. 74 , ( 5 ) 611 - 620 .

Tshuma N, Glynn N, Evanson J, Powles T, Drake WM ( 2018 ) . Hypothalamitis and severe hypothalamic dysfunction associated with anti–programmed cell death ligand 1 antibody treatment . European Journal of Cancer vol. 104 , 247 - 249 .

Powles T ( 2018 ) . Re: Nivolumab plus Ipilimumab Versus Sunitinib in Advanced Renal-cell Carcinoma . European Urology vol. 74 , ( 5 ) 679 - 680 .

Mansukhani S, Barber LJ, Kleftogiannis D, Moorcraft SY, Davidson M, Woolston A, Proszek PZ, Griffiths B et al. ( 2018 ) . Ultra-Sensitive mutation detection and genome-wide DNA copy number reconstruction by error- corrected circulating tumor DNA sequencing . Clinical Chemistry vol. 64 , ( 11 ) 1626 - 1635 .

Wong YNS, Joshi K, Khetrapal P, Ismail M, Reading JL, Sunderland MW, Georgiou A, Furness AJS et al. ( 2018 ) . Urine-derived lymphocytes as a non-invasive measure of the bladder tumor immune microenvironment . Journal of Experimental Medicine vol. 215 , ( 11 ) 2748 - 2759 .

Castellano D, Duran I, Rodríguez-Vida A, Crabb SJ, van der Heijden MS, Font Pous A, Gravis G, Anido Herranz U et al. ( 2018 ) . A phase II study investigating the safety and efficacy of neoadjuvent atezolizumab in muscle invasive bladder cancer (ABACUS) . Annals of oncology : official journal of the European Society for Medical Oncology vol. 29 ,

Galsky MD, Banchereau R, Kadel EE, Ramirez-Montagut T, Mariathasan S, Thåström A, Rosenberg J, Powles T et al. ( 2018 ) . Biological features and clinical outcomes in atezolizumab (atezo)-treated patients (pts) with metastatic urothelial cancer (mUC) of the upper vs lower urinary tract (UTUC vs LTUC) . Annals of oncology : official journal of the European Society for Medical Oncology vol. 29 ,

Powles T, Morrison L ( 2018 ) . Biomarker challenges for immune checkpoint inhibitors in urothelial carcinoma . Nature Reviews Urology vol. 15 , ( 10 ) 585 - 587 .

Gomez de Liano Lista A, Venugopal B, Fife K, Symeonides S, Vasudev NS, Rudman SM, Vohra S, Khasati L et al. ( 2018 ) . Cabozantinib in metastatic renal cell carcinoma (mRCC): Data from UK expanded access program (EAP) . Annals of oncology : official journal of the European Society for Medical Oncology . vol. 29 ,

Rini BI, Tannir NM, Escudier B, McDermott DF, Grimm MO, Porta C, Powles T, Kollmannsberger CK et al. ( 2018 ) . Characterization of response to nivolumab plus ipilimumab (N+I) or sunitinib (S) in patients (Pts) with previously untreated advanced renal cell carcinoma (arcc): Checkmate 214 . Annals of oncology : official journal of the European Society for Medical Oncology vol. 29 , viii309 - viii310 .

Petrylak DP, Rosenberg J, Duran I, Loriot Y, Sonpavde G, Wu C, Gartner E, Melhem-Bertrandt A et al. ( 2018 ) . EV-301: An open-label, randomized phase III study to evaluate enfortumab vedotin versus chemotherapy in patients with previously treated locally advanced or metastatic urothelial cancer (la/mUC) . Annals of oncology : official journal of the European Society for Medical Oncology vol. 29 ,

Rini BI, Huseni M, Atkins MB, McDermott DF, Powles TB, Escudier B, Banchereau R, Liu LF et al. ( 2018 ) . Molecular correlates differentiate response to atezolizumab (atezo) + bevacizumab (bev) vs sunitinib (sun): Results from a phase III study (IMmotion151) in untreated metastatic renal cell carcinoma (mRCC) . Annals of oncology : official journal of the European Society for Medical Oncology . vol. 29 , viii724 - viii725 .

Choueiri TK, Flaifel A, Xie W, Braun D, Ficial M, Jennings R, Nassar A, Escudier B et al. ( 2018 ) . PD-L1 status and clinical outcomes to cabozantinib, sunitinib and everolimus in patients with metastatic clear-cell RCC treated on CABOSUN and METEOR clinical trials . Annals of oncology : official journal of the European Society for Medical Oncology . vol. 29 ,

Collinson F, Brown S, Buckley H, Ainsworth G, Howard H, Poad H, Carr G, Banks RE et al. ( 2018 ) . PRISM: A randomised phase II trial of nivolumab in combination with alternatively scheduled ipilimumab in first-line treatment of patients with advanced or metastatic renal cell carcinoma . Annals of oncology : official journal of the European Society for Medical Oncology vol. 29 ,

Crusz SM, Radunovic A, Shepherd S, Shah S, Newey V, Phillips M, Lim L, Powles T et al. ( 2018 ) . Rituximab in the treatment of pembrolizumab-induced myasthenia gravis . European Journal of Cancer vol. 102 , 49 - 51 .

Suarez C, Choueiri TK, McDermott DF, Escudier B, Atkins MB, Powles TB, Rini BI, Motzer RJ et al. ( 2018 ) . Safety and tolerability of atezolizumab (atezo) plus bevacizumab (bev) vs sunitinib (sun) in untreated metastatic renal cell carcinoma (mRCC): Pooled analysis of IMmotion150 and IMmotion151 . Annals of oncology : official journal of the European Society for Medical Oncology . vol. 29 ,

McDermott DF, Rini BI, Motzer RJ, Tannir NM, Escudier B, Kollmannsberger CK, Hammers HJ, Porta C et al. ( 2018 ) . Treatment-free interval (TFI) following discontinuation of first-line nivolumab plus ipilimumab (N+I) or sunitinib (S) in patients (Pts) with advanced renal cell carcinoma (aRCC): CheckMate 214 analysis . Annals of oncology : official journal of the European Society for Medical Oncology . vol. 29 ,

Powles T, Motzer RJ, Escudier B, Pal S, Kollmannsberger C, Pikiel J, Gurney H, Rha SY et al. ( 2018 ) . Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma . British Journal of Cancer vol. 119 , ( 6 ) 663 - 669 .

Powles T ( 2018 ) . Choosing Front-line Treatment for Metastatic Renal Cancer: Which Data Are Meaningful? . European Urology vol. 74 , ( 3 ) 322 - 323 .

Hahn NM, Necchi A, Loriot Y, Powles T, Plimack ER, Sonpavde G, Roupret M, Kamat AM ( 2018 ) . Role of Checkpoint Inhibition in Localized Bladder Cancer . European Urology Oncology vol. 1 , ( 3 ) 190 - 198 .

Barata PC, De Liano AG, Mendiratta P, Crolley V, Szabados B, Morrison L, Wood L, Allman K et al. ( 2018 ) . The efficacy of VEGFR TKI therapy after progression on immune combination therapy in metastatic renal cell carcinoma . British Journal of Cancer vol. 119 , ( 2 ) 160 - 163 .

Jepson M, Elliott D, Conefrey C, Wade J, Rooshenas L, Wilson C, Beard D, Blazeby JM et al. ( 2018 ) . An observational study showed that explaining randomization using gambling-related metaphors and computer-agency descriptions impeded randomized clinical trial recruitment . Journal of Clinical Epidemiology vol. 99 , 75 - 83 .

McDermott DF, Huseni MA, Atkins MB, Motzer RJ, Rini BI, Escudier B, Fong L, Joseph RW et al. ( 2018 ) . Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma . Nature Medicine vol. 24 , ( 6 ) 749 - 757 .

Motzer RJ, Escudier B, Powles T, Scheffold C, Choueiri TK ( 2018 ) . Long-term follow-up of overall survival for cabozantinib versus everolimus in advanced renal cell carcinoma . British Journal of Cancer vol. 118 , ( 9 ) 1176 - 1178 .

Motzer RJ, Tannir NM, McDermott DF, Arén Frontera O, Melichar B, Choueiri TK, Plimack ER, Barthélémy P et al. ( 2018 ) . Nivolumab plus Ipilimumab versus Sunitinib in advanced renal-cell carcinoma . New England Journal of Medicine vol. 378 , ( 14 ) 1277 - 1290 .

Boustani J, Bertaut A, Galsky MD, Rosenberg JE, Bellmunt J, Powles T, Recine F, Harshman LC et al. ( 2018 ) . Radical cystectomy or bladder preservation with radiochemotherapy in elderly patients with muscle-invasive bladder cancer: Retrospective International Study of Cancers of the Urothelial Tract (RISC) Investigators . Acta Oncologica vol. 57 , ( 4 ) 491 - 497 .

Powles T, Necchi A, Rosen G, Hariharan S, Apolo AB ( 2018 ) . Anti–Programmed Cell Death 1/Ligand 1 (PD-1/PD-L1) Antibodies for the Treatment of Urothelial Carcinoma: State of the Art and Future Development . Clinical Genitourinary Cancer vol. 16 , ( 2 ) 117 - 129 .

Petrylak DP, Powles T, Bellmunt J, Braiteh F, Loriot Y, Morales-Barrera R, Burris HA, Kim JW et al. ( 2018 ) . Atezolizumab (MPDL3280A) monotherapy for patients with metastatic urothelial cancer long-term outcomes from a phase 1 study . JAMA Oncology vol. 4 , ( 4 ) 537 - 544 .

Necchi A, Pond GR, Pal SK, Agarwal N, Bowles DW, Plimack ER, Yu EY, Ladoire S et al. ( 2018 ) . Bone Metastases as the Only Metastatic Site in Patients With Urothelial Carcinoma: Focus on a Special Patient Population . Clinical Genitourinary Cancer vol. 16 , ( 2 ) e483 - e490 .

Choueiri TK, Larkin J, Oya M, Thistlethwaite F, Martignoni M, Nathan P, Powles T, McDermott D et al. ( 2018 ) . Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial . The Lancet Oncology vol. 19 , ( 4 ) 451 - 460 .

Escudier B, Powles T, Motzer RJ, Olencki T, Frontera OA, Oudard S, Rolland F, Tomczak P et al. ( 2018 ) . Cabozantinib, a new standard of care for patients with advanced renal cell carcinoma and bone metastases? Subgroup analysis of the METEOR trial . Journal of Clinical Oncology vol. 36 , ( 8 ) 765 - 772 .

Cella D, Escudier B, Tannir NM, Powles T, Donskov F, Peltola K, Schmidinger M, Heng DYC et al. ( 2018 ) . Quality of life outcomes for cabozantinib versus everolimus in patients with metastatic renal cell carcinoma: METEOR phase III randomized trial . Journal of Clinical Oncology vol. 36 , ( 8 ) 757 - 764 .

Perez-Gracia JL, Loriot Y, Rosenberg JE, Powles T, Necchi A, Hussain SA, Morales-Barrera R, Retz MM et al. ( 2018 ) . Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Outcomes by Prior Number of Regimens . European Urology vol. 73 , ( 3 ) 462 - 468 .

Powles T, Albiges L, Staehler M, Bensalah K, Dabestani S, Giles RH, Hofmann F, Hora M et al. ( 2018 ) . Updated European Association of Urology Guidelines: Recommendations for the Treatment of First-line Metastatic Clear Cell Renal Cancer . European Urology vol. 73 , ( 3 ) 311 - 315 .

Powles T, Durán I, van der Heijden MS, Loriot Y, Vogelzang NJ, De Giorgi U, Oudard S, Retz MM et al. ( 2018 ) . Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial . The Lancet vol. 391 , ( 10122 ) 748 - 757 .

Mariathasan S, Turley SJ, Nickles D, Castiglioni A, Yuen K, Wang Y, Kadel EE, Koeppen H et al. ( 2018 ) . TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells . Nature vol. 554 , ( 7693 ) 544 - 548 .

Bamias A, Tzannis K, Harshman LC, Crabb SJ, Wong YN, Kumar Pal S, De Giorgi U, Ladoire S et al. ( 2018 ) . Impact of contemporary patterns of chemotherapy utilization on survival in patients with advanced cancer of the urinary tract: A Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC) . Annals of Oncology vol. 29 , ( 2 ) 361 - 369 .

Ramos JD, Wingate JT, Gulati R, Plimack ER, Harshman LC, Powles T, Crabb SJ, Niegisch G et al. ( 2018 ) . Venous Thromboembolism Risk in Patients With Locoregional Urothelial Tract Tumors . Clinical Genitourinary Cancer vol. 16 , ( 1 ) e161 - e167 .

Honecker F, Aparicio J, Berney D, Beyer J, Bokemeyer C, Cathomas R, Clarke N, Cohn-Cedermark G et al. ( 2018 ) . ESMO consensus conference on testicular germ cell cancer: Diagnosis, treatment and follow-up . Annals of Oncology vol. 29 , ( 8 ) 1658 - 1686 .

Stephen Hodi F, Ballinger M, Lyons B, Soria JC, Nishino M, Tabernero J, Powles T, Smith D et al. ( 2018 ) . Immune-modified response evaluation criteria in solid tumors (imrecist): Refining guidelines to assess the clinical benefit of cancer immunotherapy . Journal of Clinical Oncology vol. 36 , ( 9 ) 850 - 858 .

Bene GD, Calabrò F, Giannarelli D, Plimack ER, Harshman LC, Yu EY, Crabb SJ, Pal SK et al. ( 2018 ) . Neoadjuvant vs. Adjuvant chemotherapy in muscle invasive bladder cancer (MIBC): Analysis from the RISC database . Frontiers in Oncology vol. 8 , ( NOV )

Mariathasan S, Turley SJ, Nickles D, Castiglioni A, Yuen K, Wang Y, Edward E K, Koeppen H et al. ( 2017 ) . TGF-β signalling attenuates tumour response to PD-L1 checkpoint blockade by contributing to retention of T cells in the peritumoural stroma . Annals of Oncology vol. 28 ,

Petrylak DP, de Wit R, Chi KN, Drakaki A, Sternberg CN, Nishiyama H, Castellano D, Hussain S et al. ( 2017 ) . Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial . The Lancet vol. 390 , ( 10109 ) 2266 - 2277 .

Balar AV, Castellano D, O'Donnell PH, Grivas P, Vuky J, Powles T, Plimack ER, Hahn NM et al. ( 2017 ) . First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study . The Lancet Oncology vol. 18 , ( 11 ) 1483 - 1492 .

Tandstad T, Kollmannsberger CK, Roth BJ, Jeldres C, Gillessen S, Fizazi K, Daneshmand S, Lowrance WT et al. ( 2017 ) . Practice makes perfect: The rest of the story in testicular cancer as a model curable neoplasm . Journal of Clinical Oncology vol. 35 , ( 31 ) 3525 - 3528 .

Powles T, Gómez de Liaño A, Ackerman C ( 2017 ) . Reply to Pontus Eriksson, Gottfrid Sjödahl, and Fredrik Liedberg's Letter to the Editor re: Thomas Powles, Robert A. Huddart, Tony Elliott, et al. Phase III, Double-blind, Randomized Trial that Compared Maintenance Lapatinib versus Placebo after First-line Chemotherapy in Patients with Human Epidermal Growth Factor Receptor 1/2-positive Metastatic Bladder Cancer. J Clin Oncol 2017;35:48–55. Knowing HER2 Status is Not Enough: A Molecular Subtype Approach to Bladder Cancer is Also Needed: Protein Expression to Predict Outcome to Targeted Therapy in Bladder Cancer: Too Little, Too Late? . European Urology vol. 72 , ( 5 ) e137 - e138 .

Paul J, Kelly C, Stobo J, Powles T ( 2017 ) . Reply to M. Horiguchi et al . Journal of Clinical Oncology vol. 35 , ( 29 )

Powles T, Smith K, Stenzl A, Bedke J ( 2017 ) . Immune Checkpoint Inhibition in Metastatic Urothelial Cancer . European Urology vol. 72 , ( 4 ) 477 - 481 .

Choueiri TK, Plimack E, Arkenau HT, Jonasch E, Heng DYC, Powles T, Frigault MM, Clark EA et al. ( 2017 ) . Biomarker-based phase II trial of savolitinib in patients with advanced papillary renal cell cancer . Journal of Clinical Oncology vol. 35 , ( 26 ) 2993 - 3001 .

Bamias A, Tzannis K, Bamia C, Harshman LC, Crabb S, Wong Y-N, Pal SK, De Giorgi U et al. ( 2017 ) . Impact of cisplatin-based therapy on long-term survival in advanced urinary tract cancer (aUTC). A retrospective international study of invasive/advanced cancer of the urothelium (RISC) . ANNALS OF ONCOLOGY . vol. 28 ,

Choueiri TK, Powles T, Zhang T, Quinn DI, Gschwend JE, Wan SS, Poehlein C ( 2017 ) . KEYNOTE-564: Phase 3 trial of pembrolizumab in the adjuvant treatment of renal cell carcinoma (RCC) . ANNALS OF ONCOLOGY . vol. 28 ,

Powles T, Motzer RJ, George DJ, Jonasch E, Pal S, Tannir NM, Signoretti S, Mai TH et al. ( 2017 ) . Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib (c) vs everolimus (e) in advanced renal cell carcinoma (rcc) . ANNALS OF ONCOLOGY . vol. 28 ,

Necchi A, Pond GR, Pal SK, Agarwal N, Bowles D, Plimack E, Yu EY, Ladoire S et al. ( 2017 ) . Outcomes of patients with metastatic urothelial carcinoma (mUC) with exclusive bone metastases: Focus on a special patient population . ANNALS OF ONCOLOGY . vol. 28 ,

Grivas P, Plimack E, Balar AV, Castellano D, O'Donnell PH, Bellmunt J, Powles T, Hahn N et al. ( 2017 ) . Pembrolizumab (pembro) as first-line therapy in cisplatin-ineligible advanced urothelial cancer (UC): Outcomes from KEYNOTE-052 in senior patients (pts) with poor performance status . ANNALS OF ONCOLOGY . vol. 28 ,

Powles T, Gschwend JE, Loriot Y, Bellmunt J, Geczi L, Vulsteke C, Abdelsalam M, Gafanov R et al. ( 2017 ) . Pembrolizumab +/- chemotherapy versus chemotherapy in advanced urothelial cancer: Phase 3 KEYNOTE-361 trial . ANNALS OF ONCOLOGY . vol. 28 ,

Petrylak DP, Chi KN, Drakaki A, Sternberg CN, de Wit R, Nishiyama H, Yu EY, Castellano D et al. ( 2017 ) . RANGE: A randomized, double-blind, placebo-controlled phase 3 study of docetaxel (DOC) with or without ramucirumab (RAM) in platinum-refractory advanced or metastatic urothelial carcinoma . ANNALS OF ONCOLOGY . vol. 28 ,

Lista AGDL, Necchi A, Lavaud P, Carles Galceran J, Castellano D, Ravaud A, Duran I, van Dijk N et al. ( 2017 ) . Treatment and outcome after Immune checkpoint inhibitors (ICI) in metastatic Urothelial Carcinoma (mUC): A European perspective . ANNALS OF ONCOLOGY . vol. 28 ,

Badreldin W, Powles T, Menard L, Ho-Yen C, Kermorgant S ( 2017 ) . Understanding and targeting Met signalling in bladder cancer . ANNALS OF ONCOLOGY . vol. 28 ,

Wong YNS, Joshi K, Khetrapal P, Ismail M, Linares J, Akarca AU, Reading JL, Furness A et al. ( 2017 ) . Urine-derived lymphocytes (UDLs) as a non-invasive surrogate marker of tumour infiltrating lymphocytes (TILs) in patients with muscle invasive bladder cancer (MIBC) . ANNALS OF ONCOLOGY . vol. 28 ,

Powles T, O'Donnell PH, Massard C, Arkenau H-T, Friedlander TW, Hoimes CJ, Lee JL, Ong M et al. ( 2017 ) . Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma: Updated Results From a Phase 1/2 Open-label Study . JAMA Oncol vol. 3 , ( 9 ) e172411 - e172411 .

Powles T ( 2017 ) . Interview with Thomas Powles: The use of durvalumab in urothelial cancer - The latest strides in immuno-oncology . Future Oncology vol. 13 , ( 18 ) 1581 - 1583 .

Lubbock ALR, Stewart GD, O'Mahony FC, Laird A, Mullen P, O'Donnell M, Powles T, Harrison DJ et al. ( 2017 ) . Overcoming intratumoural heterogeneity for reproducible molecular risk stratification: A case study in advanced kidney cancer . BMC Medicine vol. 15 , ( 1 )

Van Neste C, Laird A, O¿Mahony F, Van Criekinge W, Deforce D, Van Nieuwerburgh F, Powles T, Harrison DJ et al. ( 2017 ) . Epigenetic sampling effects: nephrectomy modifies the clear cell renal cell cancer methylome . Cellular Oncology vol. 40 , ( 3 ) 293 - 297 .

Jones RJ, Hussain SA, Protheroe AS, Birtle A, Chakraborti P, Huddart RA, Jagdev S, Bahl A et al. ( 2017 ) . Randomized phase II study investigating pazopanib versus weekly paclitaxel in relapsed or progressive urothelial cancer . Journal of Clinical Oncology vol. 35 , ( 16 ) 1770 - 1777 .

Kuusk T, Albiges L, Escudier B, Grivas N, Haanen J, Powles T, Bex A ( 2017 ) . Antiangiogenic therapy combined with immune checkpoint blockade in renal cancer . Angiogenesis vol. 20 , ( 2 ) 205 - 215 .

Bex A, Albiges L, Ljungberg B, Bensalah K, Dabestani S, Giles RH, Hofmann F, Hora M et al. ( 2017 ) . Updated European Association of Urology Guidelines Regarding Adjuvant Therapy for Renal Cell Carcinoma . European Urology vol. 71 , ( 5 ) 719 - 722 .

González-Billalabeitia E, Sepúlveda JM, Maroto P, Aparicio J, Arranz JA, Esteban E, Gironés R, López-Brea M et al. ( 2017 ) . Consensus Recommendations from the Spanish Germ Cell Cancer Group on the Use of High-dose Chemotherapy in Germ Cell Cancer . European Urology Focus vol. 3 , ( 2-3 ) 280 - 286 .

Sonpavde G, Pond GR, Mullane S, Ramirez AA, Vogelzang NJ, Necchi A, Powles T, Bellmunt J ( 2017 ) . Outcomes in patients with advanced urothelial carcinoma after discontinuation of programmed death (PD)-1 or PD ligand 1 inhibitor therapy . BJU International . vol. 119 , 579 - 584 .

Fernández-Pello S, Hofmann F, Tahbaz R, Marconi L, Lam TB, Albiges L, Bensalah K, Canfield SE et al. ( 2017 ) . A Systematic Review and Meta-analysis Comparing the Effectiveness and Adverse Effects of Different Systemic Treatments for Non-clear Cell Renal Cell Carcinoma . European Urology vol. 71 , ( 3 ) 426 - 436 .

Bellmunt J, Powles T, Vogelzang NJ ( 2017 ) . A review on the evolution of PD-1/PD-L1 immunotherapy for bladder cancer: The future is now . Cancer Treatment Reviews vol. 54 , 58 - 67 .

Necchi A, Sonpavde G, Lo Vullo S, Giardiello D, Bamias A, Crabb SJ, Harshman LC, Bellmunt J et al. ( 2017 ) . Nomogram-based Prediction of Overall Survival in Patients with Metastatic Urothelial Carcinoma Receiving First-line Platinum-based Chemotherapy: Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC) . European Urology vol. 71 , ( 2 ) 281 - 289 .

BALKWILL F, Berlato C, Khan MN, Schioppa T, Thompson R, Maniati E, Montfort A, Jangani M et al. ( 2017 ) . A CCR4 antagonist reverses the tumor-promoting microenvironment of renal cancer . Journal of Clinical Investigation

Balar AV, Galsky MD, Rosenberg JE, Powles T, Petrylak DP, Bellmunt J, Loriot Y, Necchi A et al. ( 2017 ) . Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial . The Lancet vol. 389 , ( 10064 ) 67 - 76 .

Ramos JD, Casey MF, Crabb SJ, Bamias A, Harshman LC, Wong YN, Bellmunt J, De Giorgi U et al. ( 2017 ) . Venous thromboembolism in metastatic urothelial carcinoma or variant histologies: incidence, associative factors, and effect on survival . Cancer Medicine vol. 6 , ( 1 ) 186 - 194 .

Stewart GD, De Santis M, Escudier B, Powles T, Sonpavde G ( 2016 ) . Immunotherapy for Renal Cancer: Sequencing and Combinations . European Urology Focus vol. 2 , ( 6 ) 582 - 588 .

Bex A, Ljungberg B, van Poppel H, Powles T ( 2016 ) . The Role of Cytoreductive Nephrectomy: European Association of Urology Recommendations in 2016 . European Urology vol. 70 , ( 6 ) 901 - 905 .

Crusz SM, Tang YZ, Sarker SJ, Prevoo W, Kiyani I, Beltran L, Peters J, Sahdev A et al. ( 2016 ) . Heterogeneous response and progression patterns reveal phenotypic heterogeneity of tyrosine kinase inhibitor response in metastatic renal cell carcinoma . BMC Medicine vol. 14 , ( 1 ) 185 - 185 .

Powles THOMAS, Huddart RA, Elliott T, SARKER S-J, Ackerman CHARLOTTE, Jones R, Hussaine S, Crabb S et al. ( 2016 ) . A phase II/III, double-blind, randomized trial comparing maintenance lapatinib versus placebo after first line chemotherapy in HER1/2 positive metastatic bladder cancer patients . Journal of Clinical Oncology

Powles T, Grivas P, Aragon-Ching JB, Faroun Y, Kessler ER, Tomita Y, Chakrabarti D, Laliberte RJ et al. ( 2016 ) . A multicentre, international, randomised, open-label phase 3 trial of avelumab + best supportive care (BSC) vs BSC alone as maintenance therapy after first-line platinum-based chemotherapy in patients with advanced urothelial cancer (JAVELIN bladder 100) . Annals of Oncology vol. 27 ,

Bamias A, Tzannis K, Liontos M, Crabb SJ, Harshman L, De Giorgi U, Bellmunt J, Wong YN et al. ( 2016 ) . Adherence to cisplatin-based regimens prescription in “fit” patients fulfilling platinum eligibility criteria. Impact on outcomes: a retrospective international study of invasive/advanced cancer of the urothelium (RISC) analysis . Annals of Oncology . vol. 27 ,

Tannir N, Powles T, Motzer RJ, Rolland F, Gravis G, Staehler M, Rink M, Retz M et al. ( 2016 ) . Analysis of regional differences in the phase 3 METEOR study of cabozantinib (cabo) versus everolimus (eve) in advanced renal cell carcinoma (RCC) . Annals of Oncology . vol. 27 ,

Loriot Y, Rosenberg JE, Powles TB, Necchi A, Hussain S, Morales R, Retz M, Niegisch G et al. ( 2016 ) . Atezolizumab (atezo) in platinum (plat)-treated locally advanced/metastatic urothelial carcinoma (mUC): Updated OS, safety and biomarkers from the Ph II IMvigor210 study . Annals of Oncology . vol. 27 ,

Heng D, Park J, Signorovitch JE, Yang H, Song J, Weiss J, Dezzani L, Powles TB ( 2016 ) . Clinical outcomes and dosing patterns of 2nd targeted therapy in metastatic renal carcinoma: a retrospective chart review in the EU . Annals of Oncology vol. 27 ,

Powles TB, Escudier B, de Souza P, Chowdhury S, Pook D, Harmenberg U, Basappa N, Geynisman D et al. ( 2016 ) . Efficacy of cabozantinib (cabo) vs everolimus (eve) by metastatic site and tumor burden in patients (pts) with advanced renal cell carcinoma (RCC) in the phase 3 METEOR trial . Annals of Oncology . vol. 27 ,

Hessel C, Mangeshkar M, Motzer RJ, Escudier B, Powles TB, Schwab G, Choueiri TK ( 2016 ) . Evaluation of the novel “trial within a trial” design of METEOR, a randomized phase 3 trial of cabozantinib versus everolimus in patients (pts) with advanced renal cell carcinoma (RCC) . Annals of Oncology . vol. 27 ,

Bamias A, Tzannis K, Liontos M, Harshman L, Crabb SJ, Wong YN, Pal SK, Powles TB et al. ( 2016 ) . Patterns of chemotherapy utilization in metastatic urothelial cancer (mUC): analysis from the retrospective international study of invasive/advanced cancer of the urothelium (RISC) database . Annals of Oncology . vol. 27 ,

Balar A, Bellmunt J, O'Donnell PH, Castellano D, Grivas P, Vuky J, Powles T, Plimack ER et al. ( 2016 ) . Pembrolizumab (pembro) as first-line therapy for advanced/unresectable or metastatic urothelial cancer: Preliminary results from the phase 2 KEYNOTE-052 study . Annals of Oncology . vol. 27 ,

Cella D, Escudier B, Tannir N, Powles T, Donskov F, Peltola K, Schmidinger M, Heng D et al. ( 2016 ) . Quality of life (QoL) in the phase 3 METEOR trial of cabozantinib vs everolimus for advanced renal cell carcinoma (RCC) . Annals of Oncology . vol. 27 ,

Lardas M, Stewart F, Scrimgeour D, Hofmann F, Marconi L, Dabestani S, Bex A, Volpe A et al. ( 2016 ) . Systematic Review of Surgical Management of Nonmetastatic Renal Cell Carcinoma with Vena Caval Thrombus . European Urology vol. 70 , ( 2 ) 265 - 280 .

Powles T ( 2016 ) . Where next in kidney cancer? . Annals of Oncology vol. 27 , ( 8 ) 1376 - 1377 .

Choueiri TK, Escudier B, Powles T, Tannir NM, Mainwaring PN, Rini BI, Hammers HJ, Donskov F et al. ( 2016 ) . Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial . The Lancet Oncology vol. 17 , ( 7 ) 917 - 927 .

Feber A, Worth DC, Chakravarthy A, de Winter P, Shah K, Arya M, Saqib M, Nigam R et al. ( 2016 ) . CSN1 Somatic Mutations in Penile Squamous Cell Carcinoma . Cancer Research vol. 76 , ( 16 ) 4720 - 4727 .

Powles T, Sarwar N, Stockdale A, Sarker S-J, Boleti E, Protheroe A, Jones R, Chowdhury S et al. ( 2016 ) . Safety and Efficacy of Pazopanib Therapy Prior to Planned Nephrectomy in Metastatic Clear Cell Renal Cancer . JAMA Oncology vol. 2 , ( 10 ) 1303 - 1309 .

Powles T, Lackner MR, Oudard S, Escudier B, Ralph C, Brown JE, Hawkins RE, Castellano D et al. ( 2016 ) . Randomized open-label phase II trial of apitolisib (GDC-0980), a novel inhibitor of the PI3K/mammalian target of rapamycin pathway, versus everolimus in patients with metastatic renal cell carcinoma . Journal of Clinical Oncology vol. 34 , ( 14 ) 1660 - 1668 .

Rosenberg JE, Hoffman-Censits J, Powles T, Van Der Heijden MS, Balar AV, Necchi A, Dawson N, O'Donnell PH et al. ( 2016 ) . Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: A single-arm, multicentre, phase 2 trial . The Lancet vol. 387 , ( 10031 ) 1909 - 1920 .

Powles T, Brown J, Larkin J, Jones R, Ralph C, Hawkins R, Chowdhury S, Boleti E et al. ( 2016 ) . A randomized, double-blind phase II study evaluating cediranib versus cediranib and saracatinib in patients with relapsed metastatic clear-cell renal cancer (COSAK) . Annals of Oncology vol. 27 , ( 5 ) 880 - 886 .

Stewart GD, Powles T, Van Neste C, Meynert A, O'Mahony F, Laird A, Deforce D, Van Nieuwerburgh F et al. ( 2016 ) . Dynamic epigenetic changes to VHL occur with sunitinib in metastatic clear cell renal cancer . Oncotarget vol. 7 , ( 18 ) 25241 - 25250 .

Gulley JL, Mulders P, Albers P, Banchereau J, Bolla M, Pantel K, Powles T ( 2016 ) . Perspectives on sipuleucel-T: Its role in the prostate cancer treatment paradigm . OncoImmunology vol. 5 , ( 4 )

Beaumont JL, Salsman JM, Diaz J, Deen KC, McCann L, Powles T, Hackshaw MD, Motzer RJ et al. ( 2016 ) . Quality-adjusted time without symptoms or toxicity analysis of pazopanib versus sunitinib in patients with renal cell carcinoma . Cancer vol. 122 , ( 7 ) 1108 - 1115 .

Xu CF, Johnson T, Wang X, Carpenter C, Graves AP, Warren L, Xue Z, King KS et al. ( 2016 ) . HLA-B∗57:01 confers susceptibility to pazopanib-associated liver injury in patients with cancer . Clinical Cancer Research vol. 22 , ( 6 ) 1371 - 1377 .

McDermott DF, Sosman JA, Sznol M, Massard C, Gordon MS, Hamid O, Powderly JD, Infante JR et al. ( 2016 ) . Atezolizumab, an anti-programmed death-ligand 1 antibody, in metastatic renal cell carcinoma: Long-term safety, clinical activity, and immune correlates from a phase Ia study . Journal of Clinical Oncology vol. 34 , ( 8 ) 833 - 842 .

Powles T, Wheater M, Din O, Geldart T, Boleti E, Stockdale A, Sundar S, Robinson A et al. ( 2016 ) . A Randomised Phase 2 Study of AZD2014 Versus Everolimus in Patients with VEGF-Refractory Metastatic Clear Cell Renal Cancer . European Urology . vol. 69 , 450 - 456 .

Feldman DR, Lorch A, Kramar A, Albany C, Einhorn LH, Giannatempo P, Necchi A, Flechon A et al. ( 2016 ) . Brain metastases in patients with germ cell tumors: Prognostic factors and treatment options - An analysis from the Global Germ Cell Cancer Group . Journal of Clinical Oncology vol. 34 , ( 4 ) 345 - 351 .

Powles T, Staehler M, Ljungberg B, Bensalah K, Canfield SE, Dabestani S, Giles RH, Hofmann F et al. ( 2016 ) . European Association of Urology Guidelines for Clear Cell Renal Cancers That Are Resistant to Vascular Endothelial Growth Factor Receptor–Targeted Therapy . European Urology vol. 70 , ( 5 ) 705 - 706 .

Bridgeman VL, Wan E, Foo S, Nathan MR, Welti JC, Frentzas S, Vermeulen PB, Preece N et al. ( 2016 ) . Preclinical evidence that trametinib enhances the response to antiangiogenic tyrosine kinase inhibitors in renal cell carcinoma . Molecular Cancer Therapeutics vol. 15 , ( 1 ) 172 - 183 .

Bex A, Powles T, Karam JA ( 2016 ) . Role of targeted therapy in combination with surgery in renal cell carcinoma . International Journal of Urology vol. 23 , ( 1 ) 5 - 12 .

Powles T, Staehler M, Ljungberg B, Bensalah K, Canfield SE, Dabestani S, Giles R, Hofmann F et al. ( 2016 ) . Updated EAU Guidelines for Clear Cell Renal Cancer Patients Who Fail VEGF Targeted Therapy . European Urology vol. 69 , ( 1 ) 4 - 6 .

Kramar A, Negrier S, Sylvester R, Joniau S, Mulders P, Powles T, Bex A, Bonnetain F et al. ( 2015 ) . Guidelines for the definition of time-to-event end points in renal cell cancer clinical trials: Results of the DATECAN project . Annals of Oncology vol. 26 , ( 12 ) 2392 - 2398 .

Kanu N, Grönroos E, Martinez P, Burrell RA, Yi Goh X, Bartkova J, Maya-Mendoza A, Mistrík M et al. ( 2015 ) . SETD2 loss-of-function promotes renal cancer branched evolution through replication stress and impaired DNA repair . Oncogene vol. 34 , ( 46 ) 5699 - 5708 .

Coleman R, Gray R, Powles T, Paterson A, Gnant M, Bergh J, Pritchard KI, Bliss J et al. ( 2015 ) . Adjuvant bisphosphonate treatment in early breast cancer: Meta-analyses of individual patient data from randomised trials . The Lancet vol. 386 , ( 10001 ) 1353 - 1361 .

Kurtoglu M, Davarpanah NN, Qin R, Powles T, Rosenberg JE, Apolo AB ( 2015 ) . Elevating the Horizon: Emerging Molecular and Genomic Targets in the Treatment of Advanced Urothelial Carcinoma . Clinical Genitourinary Cancer vol. 13 , ( 5 ) 410 - 420 .

Olson TA, Murray MJ, Rodriguez-Galindo C, Nicholson JC, Billmire DF, Krailo MD, Dang HM, Amatruda JF et al. ( 2015 ) . Pediatric and adolescent extracranial germ cell tumors: The road to collaboration . Journal of Clinical Oncology vol. 33 , ( 27 ) 3018 - 3028 .

Stewart GD, O'Mahony FC, Laird A, Eory L, Lubbock ALR, Mackay A, Nanda J, O'Donnell M et al. ( 2015 ) . Sunitinib treatment exacerbates intratumoral heterogeneity in metastatic renal cancer . Clinical Cancer Research vol. 21 , ( 18 ) 4212 - 4223 .

Rosenberg J, Petrylak D, Abidoye O, Van der Heijden MS, Hofman-Censits J, Necchi A, O'Donnell PH, Balmanoukian A et al. ( 2015 ) . 21LBA Atezolizumab in patients (pts) with locally-advanced or metastatic urothelial carcinoma (mUC): Results from a pivotal multicenter phase II study (IMvigor 210) . European Journal of Cancer . vol. 51 ,

Harshman L, Werner L, Wong YN, Yu E, Alva A, Crabb S, Powles T, Rosenberg J et al. ( 2015 ) . 2619 Patterns and potential benefit of adjuvant chemotherapy for residual muscle invasive disease after neoadjuvant chemotherapy for muscle invasive urothelial cancer (MIUC) . European Journal of Cancer . vol. 51 ,

Choueiri T, Escudier B, Powles T, Mainwaring P, Rini B, Donskov F, Hammers H, Hutson T et al. ( 2015 ) . 4LBA Cabozantinib versus everolimus in patients with advanced renal cell carcinoma: Results of the randomized phase 3 METEOR trial . European Journal of Cancer . vol. 51 , s708 - s709 .

Marconi L, Dabestani S, Lam TB, Hofmann F, Stewart F, Norrie J, Bex A, Bensalah K et al. ( 2015 ) . Systematic Review and Meta-analysis of Diagnostic Accuracy of Percutaneous Renal Tumour Biopsy . EUROPEAN UROLOGY vol. 69 , ( 4 ) 660 - 673 .

Powles T ( 2015 ) . Immune Checkpoint Inhibitors for Urologic Cancer: The Tip of the Iceberg? . European Urology vol. 68 , ( 2 ) 280 - 282 .

Feldman DR, Powles T ( 2015 ) . Salvage high-dose chemotherapy for germ cell tumors . Urologic Oncology: Seminars and Original Investigations vol. 33 , ( 8 ) 355 - 362 .

Mulders PF, De Santis M, Powles T, Fizazi K ( 2015 ) . Targeted treatment of metastatic castration-resistant prostate cancer with sipuleucel-T immunotherapy . Cancer Immunology, Immunotherapy vol. 64 , ( 6 ) 655 - 663 .

Powles T, Bracarda S, Chen M, Norry E, Compton N, Heise M, Hutson T, Harter P et al. ( 2015 ) . Characterisation of liver chemistry abnormalities associated with pazopanib monotherapy: A systematic review and meta-analysis of clinical trials in advanced cancer patients . European Journal of Cancer vol. 51 , ( 10 ) 1293 - 1302 .

Petrylak DP, Powles T, Bellmunt J, Braiteh FS, Loriot Y, Cruz Zambrano C, Burris HA, Kim JW et al. ( 2015 ) . A phase Ia study of MPDL3280A (anti-PDL1): Updated response and survival data in urothelial bladder cancer (UBC) . Journal of Clinical Oncology . vol. 33 , 4501 - 4501 .

Harshman LC, Werner L, Wong Y-N, Yu EY, Alva AS, Crabb SJ, Powles T, Rosenberg JE et al. ( 2015 ) . Adjuvant chemotherapy for residual disease after neoadjuvant chemotherapy for muscle invasive urothelial cancer (MIUC) . Journal of Clinical Oncology . vol. 33 , 4524 - 4524 .

De Santis M, Mulders P, Fizazi K, Gray TE, McCoy C, Stubbs A, Powles T ( 2015 ) . First prospective, open-label, phase 2 study of sipuleucel-T (sip-T) in European men with metastatic, castration-resistant prostate cancer (mCRPC) . Journal of Clinical Oncology . vol. 33 , e16015 - e16015 .

Hussain SA, Jackson R, Shields A, Dickinson L, Cornford P, Jones RJ, Lester JF, Chester JD et al. ( 2015 ) . Phase II randomised placebo controlled neoadjuvant chemotherapy study of nintedanib with gemcitabine and cisplatin in locally advanced muscle invasive bladder cancer . Journal of Clinical Oncology . vol. 33 , tps4574 - tps4574 .

Ljungberg B, Bensalah K, Canfield S, Dabestani S, Hofmann F, Hora M, Kuczyk MA, Lam T et al. ( 2015 ) . EAU guidelines on renal cell carcinoma: 2014 update . European Urology vol. 67 , ( 5 ) 913 - 924 .

Powles T ( 2015 ) . Immunotherapy: The development of immunotherapy in urothelial bladder cancer . Nature Reviews Clinical Oncology vol. 12 , ( 4 ) 193 - 194 .

Kim JW, Bellmunt J, Powles T, Loriot Y, Vogelzang NJ, Cruz Zambrano C, Burris HA, Teng S-LM et al. ( 2015 ) . Clinical activity, safety, and biomarkers of MPDL3280A in metastatic urothelial bladder cancer: Additional analysis from phase IA study . Journal of Clinical Oncology . vol. 33 , 297 - 297 .

Choueiri TK, Figueroa DJ, Fay AP, Signoretti S, Liu Y, Gagnon R, Deen K, Carpenter C et al. ( 2015 ) . Correlation of PD-L1 tumor expression and treatment outcomes in patients with renal cell carcinoma receiving sunitinib or pazopanib: Results from COMPARZ, a randomized controlled trial . Clinical Cancer Research vol. 21 , ( 5 ) 1071 - 1077 .

Stewart G, Van Neste C, Meynert A, Semple C, O'Mahony F, Laird A, Mackay A, Trooskens G et al. ( 2015 ) . Effect of sunitinib treatment on mutations and methylation in metastatic renal cancer . Journal of Clinical Oncology . vol. 33 , 492 - 492 .

Ferguson J, McKibben M, Parker JS, Wallen E, Wood CG, Powles T, Rathmell K ( 2015 ) . Evaluation of the effects of neoadjuvant pazopanib for renal cell carcinoma on intratumor genetic heterogeneity . Journal of Clinical Oncology . vol. 33 , 425 - 425 .

Fitzpatrick A, Soosaipillai G, Wilson P, Powles T, Shamash J ( 2015 ) . High Dose Interleukin-2 Therapy for Metastatic Renal Cell Carcinoma in the VEGF Targeted Era . Clinical Oncology vol. 27 , ( 3 ) e7 - e8 .

Ramos J, Casey MF, Crabb SJ, Bamias A, Harshman LC, Wong Y-N, Bellmunt J, De Giorgi U et al. ( 2015 ) . Impact of chemotherapy (CTX) on venous thromboembolism (VTE) and prognostic implications in patients with metastatic urinary tract tumors (UTT) . Journal of Clinical Oncology . vol. 33 , 318 - 318 .

Rodriguez-Vida A, Bianchini D, Van Hemelrijck M, Hughes S, Malik Z, Powles T, Bahl A, Rudman S et al. ( 2015 ) . Is there an antiandrogen withdrawal syndrome with enzalutamide? . BJU International vol. 115 , ( 3 ) 373 - 380 .

Albiges L, Choueiri T, Escudier B, Galsky M, George D, Hofmann F, Lam T, Motzer R et al. ( 2015 ) . A systematic review of sequencing and combinations of systemic therapy in metastatic renal cancer . Eur Urol vol. 67 , ( 1 ) 100 - 110 .

Choueiri TK, Escudier B, Powles T, Mainwaring PN, Rini BI, Donskov F, Hammers H, Hutson TE et al. ( 2015 ) . Cabozantinib versus everolimus in advanced renal-cell carcinoma . New England Journal of Medicine vol. 373 , ( 19 ) 1814 - 1823 .

Galsky MD, Pal SK, Chowdhury S, Harshman LC, Crabb SJ, Wong YN, Yu EY, Powles T et al. ( 2015 ) . Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer . Cancer vol. 121 , ( 15 ) 2586 - 2593 .

Gurung PMS, Veerakumarasivam A, Williamson M, Counsell N, Douglas J, Tan WS, Feber A, Crabb SJ et al. ( 2015 ) . Loss of expression of the tumour suppressor gene AIMP3 predicts survival following radiotherapy in muscle-invasive bladder cancer . International Journal of Cancer vol. 136 , ( 3 ) 709 - 720 .

Kollmannsberger C, Tandstad T, Bedard PL, Cohn-Cedermark G, Chung PW, Jewett MA, Powles T, Warde PR et al. ( 2015 ) . Patterns of relapse in patients with clinical stage I testicular cancer managed with active surveillance . Journal of Clinical Oncology vol. 33 , ( 1 ) 51 - 57 .

Mather SJ, Nock BA, Maina T, Gibson V, Ellison D, Murray I, Sobnack R, Colebrook S et al. ( 2014 ) . GRP receptor imaging of prostate cancer using [(99m)Tc]Demobesin 4: a first-in-man study . Mol Imaging Biol vol. 16 , ( 6 ) 888 - 895 .

Powles T, Eder JP, Fine GD, Braiteh FS, Loriot Y, Cruz C, Bellmunt J, Burris HA et al. ( 2014 ) . MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer . Nature vol. 515 , ( 7528 ) 558 - 562 .

Escudier B, Porta C, Powles T, Eisen T, Sternberg CN, Mehmud F, Cella D ( 2014 ) . Reply to S. Barni et Al and M. Sun et Al . J Clin Oncol vol. 32 , ( 33 ) 3783 - 3784 .

Choueiri TK, Escudier B, Pal SK, Jonasch E, Heng D, Powles T, Arkenau HT, Clark E et al. ( 2014 ) . 395 cMet: Proof-of-concept clinical trial with volitinib in patients with advanced papillary renal cell cancer (PRCC) . European Journal of Cancer . vol. 50 , 126 - 127 .

Stewart GD, O'Mahony FC, Laird A, Rashid S, Martin SA, Eory L, Lubbock ALR, Nanda J et al. ( 2014 ) . Carbonic anhydrase 9 expression increases with vascular endothelial growth factor-targeted therapy and is predictive of outcome in metastatic clear cell renal cancer . Eur Urol vol. 66 , ( 5 ) 956 - 963 .

Ghazaly E, Perry J, Kitromilidou C, Powles T, Joel S ( 2014 ) . Development and validation of an ultra-high performance LC-MS/MS assay for intracellular SN-38 in human solid tumour cell lines: comparison with a validated HPLC-fluorescence method . J Chromatogr B Analyt Technol Biomed Life Sci vol. 969 , 213 - 218 .

McDermott DF, Kluger HM, Sosman JA, Infante JR, Soria J-C, Hamid O, Delord J-P, Fasso M et al. ( 2014 ) . Immune correlates and long-term follow-up of a Phase Ia study of MPDL3280A, an engineered PD-L1 antibody, in patients with metastatic renal cell carcinoma (mRCC) . BJU INTERNATIONAL . vol. 114 , 12 - 12 .

Berlato C, Kahn MN, Schioppa T, Thompson R, Maniati E, Canosa M, Kulbe H, Sheldon C et al. ( 2014 ) . Abstract 1076: Antagonists of the chemokine receptor CCR4 reverse the tumor-promoting microenvironment of renal cancer . 1076 - 1076 .

Powles T, Hawkins R, Ralph C, Larkin J, Jones RJ, Chowdhury S, Boleti E, Fife K et al. ( 2014 ) . A Randomised Phase Ii Study of Cediranib with or Without Src Inhibition (Saracatinib) in Metastatic Clear Cell Renal Cancer (Rcc) Patients Resistant to Vegf Targeted Therapy . Annals of Oncology . vol. 25 ,

Powles T, Foreshew S-JS, Shamash J, Sarwar N, Crabb S, Sahdev A, Nixon J, Lim L et al. ( 2014 ) . A phase Ib study investigating the combination of everolimus and dovitinib in vascular endothelial growth factor refractory clear cell renal cancer . Eur J Cancer vol. 50 , ( 12 ) 2057 - 2064 .

Powles T, Davies R, Rini B ( 2014 ) . Mammalian target of rapamycin inhibitors: the beginning of the end or the end of the beginning? . Eur Urol vol. 66 , ( 2 ) 282 - 283 .

Bellmunt J, Pons F, Foreshew A, Fay AP, Powles T, Porta C, Bracarda S, Lampron ME et al. ( 2014 ) . Sequential Targeted Therapy After Pazopanib Therapy in Patients With Metastatic Renal Cell Cancer: Efficacy and Toxicity . CLINICAL GENITOURINARY CANCER vol. 12 , ( 4 ) 262 - 269 .

Stewart GD, Harrison DJ, Berney DM, Powles T ( 2014 ) . The molecular biology of renal cancer: another piece of the puzzle . Eur Urol vol. 66 , ( 1 ) 85 - 86 .

Powles T, Oudard S, Escudier BJ, Brown JE, Hawkins RE, Castellano DE, Ravaud A, Staehler MD et al. ( 2014 ) . A randomized phase II study of GDC-0980 versus everolimus in metastatic renal cell carcinoma (mRCC) patients (pts) after VEGF-targeted therapy (VEGF-TT) . Journal of Clinical Oncology . vol. 32 , 4525 - 4525 .

Galsky MD, Harshman LC, Crabb SJ, Wong Y-N, Yu EY, Chowdhury S, Powles T, Pal SK et al. ( 2014 ) . Comparative effectiveness of gemcitabine plus cisplatin (GC) versus methotrexate, vinblastine, doxorubicin, plus cisplatin (MVAC) as neoadjuvant therapy for muscle-invasive bladder cancer (MIBC) . Journal of Clinical Oncology . vol. 32 , 4512 - 4512 .

Powles T, Vogelzang NJ, Fine GD, Eder JP, Braiteh FS, Loriot Y, Cruz Zambrano C, Bellmunt J et al. ( 2014 ) . Inhibition of PD-L1 by MPDL3280A and clinical activity in pts with metastatic urothelial bladder cancer (UBC) . Journal of Clinical Oncology . vol. 32 , 5011 - 5011 .

Beaumont JL, Diaz J, Deen KC, McCann L, Powles T, Hackshaw MD, Motzer RJ, Cella D ( 2014 ) . Q-TWiST analysis of patients with metastatic renal cell carcinoma (mRCC) randomized to pazopanib (PAZ) or sunitinib (SUN) . Journal of Clinical Oncology . vol. 32 , 4581 - 4581 .

Escudier B, Porta C, Bono P, Powles T, Eisen T, Sternberg CN, Gschwend JE, De Giorgi U et al. ( 2014 ) . Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES Study . J Clin Oncol vol. 32 , ( 14 ) 1412 - 1418 .

Bex A, Fournier L, Lassau N, Mulders P, Nathan P, Oyen WJG, Powles T ( 2014 ) . Assessing the response to targeted therapies in renal cell carcinoma: technical insights and practical considerations . Eur Urol vol. 65 , ( 4 ) 766 - 777 .

Bharwani N, Miquel ME, Powles T, Dilks P, Shawyer A, Sahdev A, Wilson PD, Chowdhury S et al. ( 2014 ) . Diffusion-weighted and multiphase contrast-enhanced MRI as surrogate markers of response to neoadjuvant sunitinib in metastatic renal cell carcinoma . Br J Cancer vol. 110 , ( 3 ) 616 - 624 .

Fitzpatrick AM, Greenwood M, Foreshew A, Nixon J, Sahdev A, Sarwar N, Lim L, Jones RJ et al. ( 2014 ) . A phase Ib study exploring the combination of everolimus and dovitinib in VEGF-refractory clear cell renal cancer . JOURNAL OF CLINICAL ONCOLOGY . vol. 32 ,

Kwan A, Shamash J, Powles T, Ansell W, Chowdhury S, Harland SJ, Lamont A, Wade R et al. ( 2014 ) . An audit of adjuvant carboplatin in patients with stage I testicular seminoma (Anglian Germ Cell Cancer Group, UK) . JOURNAL OF CLINICAL ONCOLOGY . vol. 32 ,

Choueiri TK, Figueroa DJ, Liu Y, Gagnon RC, Deen KC, Carpenter C, Bartlett-Pandite AN, De Souza P et al. ( 2014 ) . Correlation of PDL1 tumor expression and treatment outcomes in patients with renal cell carcinoma (RCC) receiving tyrosine kinase inhibitors: COMPARZ study analysis . JOURNAL OF CLINICAL ONCOLOGY . vol. 32 ,

Rodriguez-Vida A, Bianchini D, Hughes S, Lorente D, Crawley D, Van Hemelrijck M, Voskoboynik M, Chau NM et al. ( 2014 ) . Is there an anti-androgen withdrawal effect with enzalutamide? . JOURNAL OF CLINICAL ONCOLOGY . vol. 32 ,

Stewart G, Laird A, O'Mahony F, Eory L, Lubbock A, Nanda J, O'Donnell M, Mackay A et al. ( 2014 ) . The effect of sunitinib on biomarkers and tumor heterogeneity in metastatic clear cell renal cancer . JOURNAL OF CLINICAL ONCOLOGY . vol. 32 ,

Dabestani S, Marconi L, Hofmann F, Stewart F, Lam TBL, Canfield SE, Staehler M, Powles T et al. ( 2014 ) . Local treatments for metastases of renal cell carcinoma: A systematic review . The Lancet Oncology vol. 15 , ( 12 ) e549 - e561 .

Gurung PM, Veerakumarasivam A, Williamson M, Counsell N, Douglas J, Tan WS, Feber A, Crabb SJ et al. ( 2014 ) . Loss of expression of the tumour suppressor gene AIMP3 predicts survival following radiotherapy in muscle-invasive bladder cancer . International Journal of Cancer

Patel N, Arya M, Muneer A, Powles T, Sullivan M, Hines J, Kelly J ( 2014 ) . Molecular aspects of upper tract urothelial carcinoma . Urol Oncol vol. 32 , ( 1 ) 28.e11 - 28.e20 .

Sharpe K, Stewart GD, Mackay A, Van Neste C, Rofe C, Berney D, Kayani I, Bex A et al. ( 2013 ) . The effect of VEGF-targeted therapy on biomarker expression in sequential tissue from patients with metastatic clear cell renal cancer . Clin Cancer Res vol. 19 , ( 24 ) 6924 - 6934 .

Choueiri TK, Escudier B, Powles T, Cella D, Lee Y, Laird DA, Scheffold C, Motzer RJ ( 2013 ) . A phase 3 randomized study of cabozantinib (XL184) vs everolimus in subjects with clear cell renal cell carcinoma (METEOR) . BJU INTERNATIONAL . vol. 112 , 4 - 4 .

Powles T, Kelly J ( 2013 ) . Innovation: London Cancer-multidisciplinary approach to urological cancer . Nat Rev Clin Oncol vol. 10 , ( 11 ) 609 - 610 .

Nichols CR, Roth B, Albers P, Einhorn LH, Foster R, Daneshmand S, Jewett M, Warde P et al. ( 2013 ) . Active Surveillance Is the Preferred Approach to Clinical Stage I Testicular Cancer . JOURNAL OF CLINICAL ONCOLOGY vol. 31 , ( 28 ) 3490 - 3493 .

Crusz SM, Tang YZ, Sandev A, Kayani I, Harris L, Beltran L, Peters J, Swanton C et al. ( 2013 ) . Heterogeneous response and progression patterns of renal cell carcinoma metastases in individual patients reveal intra-tumour heterogeneity of anti-angiogenic drug resistance . EUROPEAN JOURNAL OF CANCER . vol. 49 , S641 - S641 .

Lim L, Mathias J, Lampron M, Fehr M, Gruenwald V, Khan M, Crabb S, Choueiri T et al. ( 2013 ) . Liver toxicity in patients with metastatic renal cell carcinoma treated with pazopanib therapy . EUROPEAN JOURNAL OF CANCER . vol. 49 , S660 - S660 .

Hodi FS, Powles T, Cassier P, Kowanetz M, Herbst RS, Soria JC, Mokatrin A, Stroh M et al. ( 2013 ) . MPDL3280A (anti-PDL1): Clinical activity, safety and biomarkers of an engineered PD-L1 antibody in patients with locally advanced or metastatic tumors . EUROPEAN JOURNAL OF CANCER . vol. 49 , S184 - S184 .

Mulder P, De Santis M, Fizazi K, Whitmore J, Sheikh N, McCoy C, Stubbs A, Powles T ( 2013 ) . Preliminary product parameters from P11-1, a Phase 2, open-label trial of sipuleucel-T in European men with metastatic castrate-resistant prostate cancer (mCRPC) . EUROPEAN JOURNAL OF CANCER . vol. 49 , S696 - S696 .

Powles T ( 2013 ) . The mechanism of resistance to targeted therapy . EUROPEAN JOURNAL OF CANCER . vol. 49 , S38 - S38 .

Bhattacharyya M, Powles T, Mutsvangwa K, Wilson P, Oliver T, Shamash J ( 2013 ) . A phase II study of mitomycin, fluorouracil, folinic acid, and irinotecan (MFI) for the treatment of transitional cell carcinoma of the bladder . Urol Oncol vol. 31 , ( 6 ) 878 - 882 .

Powles T, Kayani I, Sharpe K, Lim L, Peters J, Stewart GD, Berney D, Sahdev A et al. ( 2013 ) . A prospective evaluation of VEGF-targeted treatment cessation in metastatic clear cell renal cancer . Ann Oncol vol. 24 , ( 8 ) 2098 - 2103 .

Rini BI, Powles T ( 2013 ) . Biology and Treatment of Advanced Renal Cell Carcinoma: A Global Perspective . SEMINARS IN ONCOLOGY vol. 40 , ( 4 ) 419 - 420 .

Powles T, Bascoul-Mollevi C, Kramar A, Lorch A, Beyer J ( 2013 ) . Prognostic impact of LDH levels in patients with relapsed/refractory seminoma . JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY vol. 139 , ( 8 ) 1311 - 1316 .

Jamal-Hanjani M, Karpathakis A, Kwan A, Mazhar D, Ansell W, Shamash J, Harper P, Rudman S et al. ( 2013 ) . Bone metastases in germ cell tumours: lessons learnt from a large retrospective study . BJU INTERNATIONAL vol. 112 , ( 2 ) 176 - 181 .

Tookman L, Rashid S, Matakidou A, Phillips M, Wilson P, Ansell W, Jamal-Hanjani M, Chowdhury S et al. ( 2013 ) . Carboplatin AUC 10 for IGCCCG good prognosis metastatic seminoma . Acta Oncol vol. 52 , ( 5 ) 987 - 993 .

Galsky MD, Hahn NM, Powles T, Hellerstedt BA, Lerner SP, Gardner TA, Yu M, O'Rourke M et al. ( 2013 ) . Gemcitabine, Cisplatin, and Sunitinib for Metastatic Urothelial Carcinoma and as Preoperative Therapy for Muscle-Invasive Bladder Cancer . CLINICAL GENITOURINARY CANCER vol. 11 , ( 2 ) 175 - 181 .

Cho DC, Sosman JA, Sznol M, Gordon MS, Hollebecque A, Hamid O, McDermott DF, Delord J-P et al. ( 2013 ) . Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with metastatic renal cell carcinoma (mRCC) . JOURNAL OF CLINICAL ONCOLOGY . vol. 31 ,

Powles T, Sarwar N, Stockdale A, Boleti E, Jones RJ, Protheroe A, Chowdhury S, Peters J et al. ( 2013 ) . Pazopanib prior to planned nephrectomy in metastatic clear cell renal cancer: A clinical and biomarker study . JOURNAL OF CLINICAL ONCOLOGY . vol. 31 ,

Galsky MD, Chowdhury S, Bellmunt J, Wong Y-N, Recine F, Pal SK, Moshier EL, Ladoire S et al. ( 2013 ) . Treatment patterns and outcomes in "real world" patients (pts) with metastatic urothelial cancer (UC) . JOURNAL OF CLINICAL ONCOLOGY . vol. 31 ,

Beyer J, Albers P, Altena R, Aparicio J, Bokemeyer C, Busch J, Cathomas R, Cavallin-Stahl E et al. ( 2013 ) . Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer . ANNALS OF ONCOLOGY vol. 24 , ( 4 ) 878 - 888 .

Hardt A, Wilson P, Powles T, Shamash J ( 2013 ) . The Outcome of Brain Metastases in Patients with Metastatic Germ Cell Tumours - Is Cranial Irradiation Necessary? . CLINICAL ONCOLOGY vol. 25 , ( 4 ) E70 - E71 .

Pal P, Roy A, Moore G, Muzslay M, Lee E, Alder S, Wilson P, Powles T et al. ( 2013 ) . Keypad mobile phones are associated with a significant increased risk of microbial contamination compared to touch screen phones . Journal of Infection Prevention vol. 14 , ( 2 ) 65 - 68 .

Powles T, Sarwar N, Jones R, Wilson P, Boleti E, Protheroe A, Crabb S, Shamash J et al. ( 2013 ) . The hazards of cross comparing the drug toxicity results from different trials in metastatic renal cancer: in response to a letter from Dr. Catalá-López . Eur J Cancer vol. 49 , ( 4 ) 986 - 987 .

Powles T, Sharpe K, Berney D, Kayani I, Doshi R, Stewart GD, Reynolds A, Bex A et al. ( 2013 ) . Dynamic molecular changes with VEGF targeted therapy in metastatic clear cell renal cancer . JOURNAL OF CLINICAL ONCOLOGY . vol. 31 ,

Powles T, Bex A ( 2013 ) . Integration of surgery in metastatic renal cancer . Renal Cell Carcinoma: Clinical Management ,

Kroon BK, de Bruijn R, Prevoo W, Horenblas S, Powles T, Bex A ( 2013 ) . Probability of Downsizing Primary Tumors of Renal Cell Carcinoma by Targeted Therapies Is Related to Size at Presentation . UROLOGY vol. 81 , ( 1 ) 111 - 115 .

Powles T, Crusz SM ( 2013 ) . Sequencing systemic therapies in advanced RCC: is there a best strategy? . Am Soc Clin Oncol Educ Book

Powles T, Kollmannsberger C, Feldman DR ( 2013 ) . The conundrum of clinical trials in adult germ-cell tumours . Lancet Oncol vol. 14 , ( 1 ) 14 - 15 .

O'Mahony FC, Nanda J, Laird A, Mullen P, Caldwell H, Overton IM, Eory L, O'Donnell M et al. ( 2013 ) . The use of reverse phase protein arrays (RPPA) to explore protein expression variation within individual renal cell cancers . Journal of visualized experiments : JoVE ( 71 )

Welti JC, Powles T, Foo S, Gourlaouen M, Preece N, Foster J, Frentzas S, Bird D et al. ( 2012 ) . Contrasting effects of sunitinib within in vivo models of metastasis . ANGIOGENESIS vol. 15 , ( 4 ) 623 - 641 .

Powles T, Albers P ( 2012 ) . Management of favorable-risk patients with metastatic renal cell carcinoma: when to start and when to stop targeted therapy . Clin Genitourin Cancer vol. 10 , ( 4 ) 213 - 218 .

Lim L, Powles T ( 2012 ) . The management of low-stage non-seminomatous germ cell tumors . Oncology Reviews vol. 6 , ( 2 ) 153 - 157 .

Powles T, Sarwar N, Jones R, Wilson P, Boleti E, Protheroe A, Crabb SJ, Shamash J et al. ( 2012 ) . An indirect comparison of the toxicity of sunitinib and pazopanib in metastatic clear cell renal cancer . Eur J Cancer vol. 48 , ( 17 ) 3171 - 3176 .

Stewart GD, O'Mahony FC, Eory L, Nanda J, Laird A, O'Donnell M, Mullen P, Riddick ACP et al. ( 2012 ) . Proteomic analysis of pre- and postsunitinib treated renal cancer tissue to assess tumour heterogeneity and differential protein expression . SCOTTISH MEDICAL JOURNAL vol. 57 , ( 4 ) 245 - 246 .

Powles TB, Jones RJ, Crabb S, Sarker S, Boleti E, Shamash J, Sarwar N, Chowdhury S ( 2012 ) . A PHASE I DOSE ESCALATION STUDY INVESTIGATING DOVITINIB AND EVEROLMUS IN COMBINATION IN METASTATIC CLEAR CELL RENAL CANCER PATIENTS WHO HAVE PREVIOUSLY FAILED VEGF TARGETED THERAPY . ANNALS OF ONCOLOGY . vol. 23 , 272 - 272 .

Meeks JJ, Bellmunt J, Bochner BH, Clarke NW, Daneshmand S, Galsky MD, Hahn NM, Lerner SP et al. ( 2012 ) . A Systematic Review of Neoadjuvant and Adjuvant Chemotherapy for Muscle-invasive Bladder Cancer . EUROPEAN UROLOGY vol. 62 , ( 3 ) 523 - 533 .

Powles T, Hutson TE ( 2012 ) . Difficulty in predicting survival in metastatic renal cancer . Lancet Oncol vol. 13 , ( 9 ) 859 - 860 .

Lim FL, Shamash J, Wilson P, Powles T ( 2012 ) . LIVER TOXICITY IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA TREATED WITH PAZOPANIB THERAPY . ANNALS OF ONCOLOGY . vol. 23 , 290 - 290 .

Porta C, Tortora G, Linassier C, Papazisis K, Awada A, Berthold D, Maroto JP, Powles T et al. ( 2012 ) . Maximising the duration of disease control in metastatic renal cell carcinoma with targeted agents: an expert agreement . MEDICAL ONCOLOGY vol. 29 , ( 3 ) 1896 - 1907 .

Birtle AJ, Lewis R, Chester J, Donovan J, Johnson M, Jones RJ, Kockelbergh R, Powles TB et al. ( 2012 ) . PERI-OPERATIVE CHEMOTHERAPY OR SURVEILLANCE IN UPPER TRACT UROTHELIAL CANCER ( POUT - CRUK/11/027) - A NEW RANDOMISED CONTROLLED TRIAL TO DEFINE STANDARD POST-OPERATIVE MANAGEMENT . ANNALS OF ONCOLOGY . vol. 23 , 292 - 292 .

Sharpe K, Lu Y, Berney D, Rofe C, Powles T ( 2012 ) . PRECLINICAL DATA INVESTIGATING THE USE OF SARACATINIB IN RENAL CELL CARCINOMA . ANNALS OF ONCOLOGY . vol. 23 , 172 - 172 .

Pons Valladares F, Choueiri TK, Hutson TE, Powles TB, Porta C, Bracarda S, Lampron ME, Cerbone L et al. ( 2012 ) . SEQUENTIAL TARGETED THERAPY FOLLOWING PAZOPANIB (PZ) IN PATIENTS (PTS) WITH METASTATIC RENAL CELL CANCER (MRCC): EFFICACY AND TOXICITY . ANNALS OF ONCOLOGY . vol. 23 , 278 - 278 .

Porta C, Powles T ( 2012 ) . Sequential therapy in metastatic renal cell carcinoma: what comes next? . MEDICAL ONCOLOGY vol. 29 , ( 3 ) 1914 - 1915 .

Blick C, Hall P, Pwint T, Al-Terkait F, Crew J, Powles T, Macaulay V, Munro N et al. ( 2012 ) . Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin (AMVAC) as neoadjuvant chemotherapy for patients with muscle-invasive transitional cell carcinoma of the bladder . CANCER vol. 118 , ( 16 ) 3920 - 3927 .

Thillai K, Allan S, Powles T, Rudman S, Chowdhury S ( 2012 ) . Neoadjuvant and adjuvant treatment of renal cell carcinoma . EXPERT REVIEW OF ANTICANCER THERAPY vol. 12 , ( 6 ) 765 - 776 .

Powles T ( 2012 ) . Second-line therapy after VEGF targeted therapy in metastatic renal cancer: a law of diminishing returns . Clin Genitourin Cancer vol. 10 , ( 2 ) 67 - 68 .

Bex A, Powles T ( 2012 ) . Selecting patients for cytoreductive nephrectomy in advanced renal cell carcinoma: who and when . EXPERT REVIEW OF ANTICANCER THERAPY vol. 12 , ( 6 ) 787 - 797 .

Rashid S, Lim L, Powles T ( 2012 ) . Treatment of relapsed/refractory germ cell tumours: an equipoise between conventional and high dose therapy . Curr Treat Options Oncol vol. 13 , ( 2 ) 201 - 211 .

Bex A, Powles T, Blank CU, Chowdhury S, Horenblas S, Peters J, Boleti E, Haanen JBAG ( 2012 ) . Outcome of rapid disease progression in the treatment break following cytoreductive nephrectomy (CN) after presurgical sunitinib in patients with primary metastatic renal cell carcinoma (RCC) . JOURNAL OF CLINICAL ONCOLOGY . vol. 30 ,

Badreldin W, Chowdhury S, Harland SJ, Mazhar D, Powles T, Wilson P, Shamash J ( 2012 ) . The efficacy of irinotecan, paclitaxel, and oxaliplatin (IPO) in relapsed germ cell tumours: A non-cisplatin-based regimen . JOURNAL OF CLINICAL ONCOLOGY . vol. 30 ,

Shamash J, Jacob J, Agrawal S, Powles T, Mutsvangwa K, Wilson P, Stebbing J ( 2012 ) . Whole blood stem cell reinfusion and escalated dose melphalan in castration-resistant prostate cancer: a phase 1 study . Clin Cancer Res vol. 18 , ( 8 ) 2352 - 2359 .

Kitromilidou C, Ghazaly E, Joel S, Powles T ( 2012 ) . COMBINING HER1-4 TARGETED THERAPIES AND CHEMOTHERAPY IN BLADDER CANCER . ANNALS OF ONCOLOGY . vol. 23 , 35 - 35 .

Stewart GD, O'Mahony F, Eory L, Nanda J, Laird A, O'Donnell M, Mullen P, Riddick A et al. ( 2012 ) . Proteomic analysis of pre- and post-sunitinib treated renal cancer tissue to assess tumor heterogeneity and differential protein expression . JOURNAL OF CLINICAL ONCOLOGY vol. 30 , ( 5 )

Karpathakis A, Jamal-Hanjani M, Kwan A, Mazhar D, Rudman SM, Powles T, Shamash J, Chowdhury S ( 2012 ) . Testicular germ cell tumors with bony metastases: Diagnosis, management, and outcomes (a case series) . JOURNAL OF CLINICAL ONCOLOGY vol. 30 , ( 5 )

Boleti E, Sarwar N, Jones RR, Chowdhury S, Crabb SJ, Shamash J, Peters J, Oades G et al. ( 2012 ) . The safety and efficacy of pazopanib prior to planned nephrectomy in metastatic clear cell renal cancer . JOURNAL OF CLINICAL ONCOLOGY vol. 30 , ( 5 )

Doshi R, O'Donnel M, Bex A, Beltran L, Sahdev A, Peters J, Harrison DJ, Stewart GD et al. ( 2012 ) . Renal Cell Carcinoma before and after Sunitinib Therapy. Morphological and Molecular Changes . LABORATORY INVESTIGATION . vol. 92 , 201A - 201A .

Gurung PMS, Williamson M, West C, Counsell N, Ahmed A, Benthani F, Feber A, Dewinter P et al. ( 2012 ) . The tumour suppressor gene, AIMP3 sensitises bladder cancer to chemo/radiotherapy in vitro and is a prognostic marker for overall survival in patients treated with radiotherapy for muscle invasive disease . EUROPEAN UROLOGY SUPPLEMENTS vol. 11 , ( 1 ) E669 - U430 .

Lim L, Powles T ( 2012 ) . New prognostic models in metastatic renal cancer . Translational Andrology and Urology vol. 1 , ( 3 ) 144 - 145 .

Shaw GL, Hussain M, Nair R, Bycroft J, Beltran L, Green JSA, Powles T, Peters JL ( 2012 ) . Performing Cytoreductive Nephrectomy following Targeted Sunitinib Therapy for Metastatic Renal Cell Carcinoma: A Surgical Perspective . UROLOGIA INTERNATIONALIS vol. 89 , ( 1 ) 83 - 88 .

Kalin M, Cima I, Schiess R, Fankhauser N, Powles T, Wild P, Templeton A, Cerny T et al. ( 2011 ) . Novel Prognostic Markers in the Serum of Patients With Castration-Resistant Prostate Cancer Derived From Quantitative Analysis of the Pten Conditional Knockout Mouse Proteome . EUR UROL vol. 60 , ( 6 ) 1235 - 1243 .

Josephs D, Hutson TE, Cowey CL, Pickering LM, Larkin JM, Gore ME, Van Hemelrijck M, McDermott DF et al. ( 2011 ) . Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with severe renal impairment or on haemodialysis . BJU INT vol. 108 , ( 8 ) 1279 - 1283 .

Josephs D, Hutson TE, Cowey CL, Pickering LM, Larkin JM, Gore ME, Van Hemelrijck M, McDermott DF et al. ( 2011 ) . Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with severe renal impairment or on haemodialysis . BJU Int vol. 108 , ( 8 ) 1279 - 1283 .

Stephenson AJ, Aprikian AG, Gilligan TD, Oldenburg J, Powles T, Toner GC, Waters WB ( 2011 ) . Management of Low-stage Nonseminomatous Germ Cell Tumors of Testis: SIU/ICUD Consensus Meeting on Germ Cell Tumors (GCT), Shanghai 2009 . UROLOGY vol. 78 , ( 4 ) S444 - S455 .

Kayani I, Avril N, Bomanji J, Chowdhury S, Rockall A, Sahdev A, Nathan P, Wilson P et al. ( 2011 ) . Sequential FDG-PET/CT as a biomarker of response to Sunitinib in metastatic clear cell renal cancer . Clin Cancer Res vol. 17 , ( 18 ) 6021 - 6028 .

Rimmer Y, Chester J, Joffe J, Stark D, Shamash J, Powles T, White J, Wason J et al. ( 2011 ) . Accelerated BEP: a phase I trial of dose-dense BEP for intermediate and poor prognosis metastatic germ cell tumour . BRIT J CANCER vol. 105 , ( 6 ) 766 - 772 .

Bex A, Powles T ( 2011 ) . Reply from Authors re: Simon P. Kim, R. Houston Thompson. Sunitinib Prior to Planned Cytoreductive Nephrectomy: Is This the New Litmus Test for Metastatic Renal Cell Carcinoma? Eur Urol 2011;60:455-6 . EUR UROL vol. 60 , ( 3 ) 456 - 457 .

Powles T, Blank C, Chowdhury S, Horenblas S, Peters J, Shamash J, Sarwar N, Boleti E et al. ( 2011 ) . The outcome of patients treated with sunitinib prior to planned nephrectomy in metastatic clear cell renal cancer . Eur Urol vol. 60 , ( 3 ) 448 - 454 .

Bex A, Powles T ( 2011 ) . Reply to The sequence of cytoreductive nephrectomy: glass half empty or glass half full? . ANN ONCOL vol. 22 , ( 7 ) 1691 - 1691 .

Lorch A, Bascoul-Mollevi C, Kramar A, Einhorn L, Necchi A, Massard C, De Giorgi U, Flechon A et al. ( 2011 ) . Conventional-Dose Versus High-Dose Chemotherapy As First Salvage Treatment in Male Patients With Metastatic Germ Cell Tumors: Evidence From a Large International Database . J CLIN ONCOL vol. 29 , ( 16 ) 2178 - 2184 .

Powles T ( 2011 ) . Stage I nonseminomatous germ cell tumor of the testis: more questions than answers? . Hematol Oncol Clin North Am vol. 25 , ( 3 ) 517 - viii .

Lerner SP, Powles T, Hahn NM, Gardner T, Cheng L, Green J, Berney D, Taber D et al. ( 2011 ) . A phase II trial of neoadjuvant cisplatin (C), gemcitabine (G), and sunitinib (S) in muscle-invasive urothelial carcinoma (miUC): Results from Hoosier Oncology Group GU07-123 trial . JOURNAL OF CLINICAL ONCOLOGY vol. 29 , ( 15 )

Fizazi K, Powles T, George DJ, Poehlein CH ( 2011 ) . A randomized, controlled phase III global trial comparing sipuleucel-T plus androgen deprivation therapy versus androgen deprivation therapy alone in men with metastatic androgen dependent (hormone sensitive) prostate cancer . JOURNAL OF CLINICAL ONCOLOGY vol. 29 , ( 15 )

Chen GJ, Sonpavde G, Vale CL, Fisher D, Powles T, ABCMAC ( 2011 ) . Association of progression-free survival (PFS) at 2 or 3 years with overall survival (OS) at 5 years for locally advanced bladder cancer (BC): Evaluation of individual patient data (IPD) from seven randomized trials comparing local therapy with or without neoadjuvant chemotherapy (NC) . JOURNAL OF CLINICAL ONCOLOGY vol. 29 , ( 15 )

Shamash J, Jacob J, Powles T, Agrawal S, Mutsvangwa K, Saunders N, Wilson P, Stebbing J ( 2011 ) . Melphalan and whole-blood stem cell reinfusion in castration-resistant prostate cancer (CRPC): A phase I/II study . JOURNAL OF CLINICAL ONCOLOGY vol. 29 , ( 15 )

Powles T, Mollevi C, Kramar A, Lorch A, Beyer J, IPFSG ( 2011 ) . The prognostic significance of LDH levels in patients with relapsed/refractory seminoma and their predictive value of the new international prognostic score . JOURNAL OF CLINICAL ONCOLOGY vol. 29 , ( 15 )

Powles T, Kayani I, Blank C, Chowdhury S, Horenblas S, Peters J, Shamash J, Sarwar N et al. ( 2011 ) . The safety and efficacy of sunitinib before planned nephrectomy in metastatic clear cell renal cancer . Annals of Oncology vol. 22 , ( 5 ) 1041 - 1047 .

Stewart GD, O'Mahony FC, Powles T, Riddick ACP, Harrison DJ, Faratian D ( 2011 ) . What can molecular pathology contribute to the management of renal cell carcinoma? . NAT REV UROL vol. 8 , ( 5 ) 255 - 265 .

Powles T, Chowdhury S, Shamash J, Bazeos A, Gillessen S, Saunders N, Lim L, Sarwar N et al. ( 2011 ) . Increased haematopoietic progenitor cells are associated with poor outcome in patients with metastatic renal cancer treated with sunitinib . Ann Oncol vol. 22 , ( 4 ) 815 - 820 .

Welti JC, Gourlaouen M, Powles T, Kudahetti SC, Wilson P, Berney DM, Reynolds AR ( 2011 ) . Fibroblast growth factor 2 regulates endothelial cell sensitivity to sunitinib . Oncogene vol. 30 , ( 10 ) 1183 - 1193 .

Hussain M, Nair R, Bycroft J, Green JSA, Powles T, Peters JL ( 2011 ) . A COMPARISON OF OPEN RADICAL NEPHRECTOMY COMPLICATION RATES IN PATIENTS TREATED WITH NEOADJUVANT SUNITINIB FOR METASTATIC RENAL CELL CARCINOMA VERSUS NON-METASTATIC RENAL CELL CARCINOMA . EUR UROL SUPPL vol. 10 , ( 2 ) 103 - 103 .

Blick C, Hall P, Pwint T, Munro N, Crew J, Powles T, Macaulay VM, Al-Terkait F et al. ( 2011 ) . Accelerated MVAC as neoadjuvant chemotherapy for patients with muscle-invasive transitional cell carcinoma of the bladder . JOURNAL OF CLINICAL ONCOLOGY vol. 29 , ( 7 )

Powles T, Chowdhury S, Avril N, Bomanji J, Shamash J, Sarwar N, Rockall A, Sahdev A et al. ( 2011 ) . Sequential FDG-PET/CT as a surrogate marker of response to sunitinib in metastatic clear cell renal cancer . JOURNAL OF CLINICAL ONCOLOGY vol. 29 , ( 7 )

Powles T, Chowdhury S, Jones R, Mantle M, Nathan P, Bex A, Lim L, Hutson T ( 2011 ) . Sunitinib and other targeted therapies for renal cell carcinoma . Br J Cancer vol. 104 , ( 5 ) 741 - 745 .

Powles T, Blank C, Chowdhury S, Peters J, Haanen J, O'Brien T, Rockall AR, Sahdev AS et al. ( 2011 ) . THE OUTCOME OF PATIENTS TREATED WITH UPFRONT SUNITINIB PRIOR TO NEPHRECTOMY IN METASTATIC CLEAR CELL RENAL CANCER . EUR UROL SUPPL vol. 10 , ( 2 ) 102 - 103 .

Shamash J, Powles T, Sarker SJ, Protheroe A, Mithal N, Mills R, Beard R, Wilson P et al. ( 2011 ) . A multi-centre randomised phase III trial of Dexamethasone vs Dexamethasone and diethylstilbestrol in castration-resistant prostate cancer: immediate vs deferred Diethylstilbestrol . BRIT J CANCER vol. 104 , ( 4 ) 620 - 628 .

Feldman DR, Huddart R, Hall E, Beyer J, Powles T ( 2011 ) . Is High Dose Therapy Superior to Conventional Dose Therapy as Initial Treatment for Relapsed Germ Cell Tumors? The TIGER Trial . JOURNAL OF CANCER vol. 2 , 374 - 377 .

Powles T, Chowdhury S, Bower M, Saunders N, Lim L, Shamash J, Sarwar N, Sadev A et al. ( 2011 ) . The Effect of Sunitinib on Immune Subsets in Metastatic Clear Cell Renal Cancer . UROL INT vol. 86 , ( 1 ) 53 - 59 .

Perry J, Ghazaly E, Kitromilidou C, McGrowder EH, Joel S, Powles T ( 2010 ) . A Synergistic interaction between lapatinib and chemotherapy agents in a panel of cell lines is due to the inhibition of the efflux pump BCRP . Molecular Cancer Therapeutics vol. 9 , ( 12 )

Bex A, Jonasch E, Kirkali Z, Mejean A, Mulders P, Oudard S, Patard JJ, Powles T et al. ( 2010 ) . Integrating Surgery with Targeted Therapies for Renal Cell Carcinoma: Current Evidence and Ongoing Trials . EUR UROL vol. 58 , ( 6 ) 819 - 828 .

Lorch A, Beyer J, Kramar A, Einhorn LH, Necchi A, Massard C, De Giorgi U, Flechon A et al. ( 2010 ) . Prognostic factors in patients with metastatic germ cell tumors who experienced treatment failure with cisplatin-based first-line chemotherapy . Journal of Clinical Oncology vol. 28 , ( 33 ) 4906 - 4911 .

Gerlinger M, Wilson P, Powles T, Shamash J ( 2010 ) . Elevated LDH predicts poor outcome of recurrent germ cell tumours treated with dose dense chemotherapy . Eur J Cancer vol. 46 , ( 16 ) 2913 - 2918 .

Poffiri E, Miscoria M, Lim L, Shamash J, Chowdhury S, Powles T ( 2010 ) . THE OUTCOME OF PATIENTS WHO FAIL SUNITINIB AND DO NOT HAVE ACCESS TO SUNITINIB THERAPY . ANNALS OF ONCOLOGY . vol. 21 , 292 - 292 .

Shamash J, Stebbing J, Sweeney C, Sonpavde G, Harland S, Dawkins G, Brock C, Abelman W et al. ( 2010 ) . A validated prognostic index predicting response to dexamethasone and diethylstilbestrol in castrate-resistant prostate cancer . Cancer vol. 116 , ( 15 ) 3595 - 3602 .

Gillessen S, Powles T, Lim L, Wilson P, Shamash J ( 2010 ) . Low-dose induction chemotherapy with Baby-BOP in patients with metastatic germ-cell tumours does not compromise outcome: a single-centre experience . Ann Oncol vol. 21 , ( 8 ) 1589 - 1593 .

Matakidou A, Mutsvangwa K, Ansell W, Lim L, Powles TB, Oliver RT, Shamash J ( 2010 ) . Single-agent carboplatin AUC10 for metastatic seminoma with IGCCCG good prognosis disease; a feasibility study of the Orchid Clinical Trials Group . Ann Oncol vol. 21 , ( 8 ) 1730 - 1731 .

Powles T, Jones R, Chowdhury S, Shamash J, Mantle M, Lim L, Hutson T ( 2010 ) . The application of the National Institute of Clinical Excellence guidelines for treatment of metastatic renal cell carcinoma in the United Kingdom: friend or foe? . BJU Int vol. 106 , ( 4 ) 453 - 457 .

Noel EE, Yeste-Velasco M, Mao X, Perry J, Kudahetti SC, Li NF, Sharp S, Chaplin T et al. ( 2010 ) . The association of CCND1 overexpression and cisplatin resistance in testicular germ cell tumors and other cancers . Am J Pathol vol. 176 , ( 6 ) 2607 - 2615 .

Avril N, Dambha F, Murray I, Shamash J, Powles T, Sahdev A ( 2010 ) . The clinical advances of fluorine-2-D-deoxyglucose--positron emission tomography/computed tomography in urological cancers . Int J Urol vol. 17 , ( 6 ) 501 - 511 .

Escudier BJ, Cella D, Gschwend JE, Powles T, Sternberg CN, Hodge R, Lau M, Neary M et al. ( 2010 ) . A randomized double-blind cross-over patient preference study of pazopanib versus sunitinib in treatment-naive locally advanced or metastatic renal cell carcinoma (mRCC) . JOURNAL OF CLINICAL ONCOLOGY vol. 28 , ( 15 )

Chowdhury S, O'Brien TS, Sarwar N, Shamash J, McGrath S, Agrawal S, Lim L, Rudman SM et al. ( 2010 ) . The effect of sunitinib on immune parameters and haemopoetic stem cell markers in patients with untreated cleat cell renal cancer . JOURNAL OF CLINICAL ONCOLOGY vol. 28 , ( 15 )

Powles T, Kayani I, Blank CU, Chowdhury S, Horenblas S, Sarwar N, Nathan PD, Boleti E et al. ( 2010 ) . The safety and efficacy of sunitinib prior to planned nephrectomy in metastatic clear cell renal cancer . Journal of Clinical Oncology vol. 28 , ( 15_suppl ) 4603 - 4603 .

Bharwani N, Miquel M, Sahdev A, Powles T, Reznek R, Rockall A ( 2010 ) . Diffusion-Weighted MRI in the Assessment of Tumor Response to Novel Targeted Therapies in Metastatic Renal Cell Carcinoma . AMERICAN JOURNAL OF ROENTGENOLOGY . vol. 194 ,

El-Hariry I, Powles T, Lau MR, Sternberg CN, Ravaud A, von der Maase H, Zantl N, Harper P et al. ( 2010 ) . Amplification of epidermal growth factor receptor gene in renal cell carcinoma . EUR J CANCER vol. 46 , ( 5 ) 859 - 862 .

Chowdhury S, Harper P, Powles T ( 2010 ) . Castration Refractory Prostate Cancer: Cinderella Finally Comes to the Ball . ONKOLOGIE vol. 33 , ( 12 ) 655 - 656 .

Matakidou A, Mutsvangwa K, Ansell W, Powles T, Oliver T, Shamash J ( 2009 ) . Single-agent Carboplatin AUC10 for Metastatic Seminoma with IGCCCG Good Prognosis Disease; a Feasibility Study of the Orchid Clinical Trials Group . CLIN ONCOL-UK vol. 21 , ( 10 ) 800 - 800 .

Perry J, Powles T, Shamash J, Veerupillai A, McGrowder E, Noel E, Lu Y-J, Oliver T et al. ( 2009 ) . The relative activity of cisplatin, oxaliplatin and satraplatin in testicular germ cell tumour sensitive and resistant cell lines . Cancer Chemother Pharmacol vol. 64 , ( 5 ) 925 - 933 .

Murugaesu N, Powles T, Bestwick J, Oliver RTD, Shamash J ( 2009 ) . Long-term follow-up of testicular cancer patients shows no predisposition to osteoporosis . Osteoporos Int vol. 20 , ( 9 ) 1627 - 1630 .

Josephs DH, Hutson TE, Pickering LM, Larkin JM, Choueiri TK, Patel TV, Mcdermott DF, Powles T et al. ( 2009 ) . Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma (mRCC) with severe renal impairment or on haemodialysis . JOURNAL OF CLINICAL ONCOLOGY . vol. 27 ,

Hahn NM, Powles T, Sweeney CJ ( 2009 ) . Development of novel agents for bladder cancer . Update on Cancer Therapeutics vol. 3 , ( 4 ) 160 - 169 .

Nathan P, Wagstaff J, Porfiri E, Powles T, Eisen T ( 2009 ) . UK guidelines for the systemic treatment of renal cell carcinoma . BRIT J HOSP MED vol. 70 , ( 5 ) 284 - 286 .

Powles T, Robinson D, Stebbing J, Nelson M, Mandalia S, Moller H, Gazzard B, Bower M ( 2009 ) . Highly active antiretroviral therapy and the incidence of non-AIDS-defining cancers in people with HIV infection . HIV MED vol. 10 , 4 - 4 .

Powles T, Stebbing J, Bazeos A, Hatzimichael E, Mandalia S, Nelson M, Gazzard B, Bower M ( 2009 ) . The role of immune suppression and HHV-8 in the increasing incidence of HIV-associated multicentric Castleman's disease . Ann Oncol vol. 20 , ( 4 ) 775 - 779 .

Gerlinger M, Wilson P, Powles T, Oliver RTD, Shamash J ( 2009 ) . ESTABLISHED PROGNOSTIC MODELS FAIL TO PREDICT THE OUTCOME OF DOSE DENSE CHEMOTHERAPY FOR THE TREATMENT OF RECURRENT GERM CELL TUMOURS (GCTS) . EUR UROL SUPPL vol. 8 , ( 4 ) 358 - 358 .

Powles T, Robinson D, Stebbing J, Shamash J, Nelson M, Gazzard B, Mandelia S, Moller H et al. ( 2009 ) . Highly Active Antiretroviral Therapy and the Incidence of Non-AIDS-Defining Cancers in People With HIV Infection . J CLIN ONCOL vol. 27 , ( 6 ) 884 - 890 .

Stancliffe M, Powles T, Bower M ( 2009 ) . HIV-related lung cancer in the age of HAART . Multidisciplinary Respiratory Medicine vol. 4 , ( 3 ) 225 - 228 .

Stebbing J, Powles T, McPherson K, Shamash J, Wells P, Sheaff MT, Slater S, Rudd RM et al. ( 2009 ) . The efficacy and safety of weekly vinorelbine in relapsed malignant pleural mesothelioma . Lung Cancer vol. 63 , ( 1 ) 94 - 97 .

Nelson M, Powles T, Zeitlin A, Sen P, Scourfield A, Bower M, Gazzard B, Stebbing J ( 2009 ) . Thyroid dysfunction and relationship to antiretroviral therapy in hiv-positive individuals in the HAART era . Journal of Acquired Immune Deficiency Syndromes vol. 50 , ( 1 ) 113 - 114 .

Oliver T, Powles T, Nargund V, Berney D ( 2008 ) . Spontaneous regression of renal cell carcinoma and the role of prognostic factors . Clinical Management of Renal Tumors ,

Jones R, Nelson M, Bower M, Powles T, Mandalia S, Gazzard B, Stebbing J ( 2008 ) . Triple-class antiretroviral agent resistance in a large cohort: Prevalence and clinical outcomes . ARCH INTERN MED vol. 168 , ( 17 ) 1926 - 1927 .

Gaughan EM, Dezube BJ, Aboulafia D, Bower M, Strebbing J, Powles T, Pantanowitz L ( 2008 ) . Human immunodeficiency virus-associated renal cell carcinoma: A transatlantic case series . CLIN GENITOURIN CANC vol. 6 , ( 2 ) 86 - 90 .

Bazoes A, Bower M, Powles T ( 2008 ) . Smoke and mirrors: HIV-related lung cancer . Curr Opin Oncol vol. 20 , ( 5 ) 529 - 533 .

Powles T, McFaul S, Stebbing J, Wilson P, Oliver T, Tranter N, Shamash J ( 2008 ) . The efficacy and safety of irinotecan cisplatin and mitomycin chemotherapy in sunitinib pre-treated metastatic clear cell renal cancer . Onco Targets Ther vol. 1 , 35 - 39 .

Bower M, Collins S, Cottrill C, Cwynarski K, Montoto S, Nelson M, Nwokolo N, Powles T et al. ( 2008 ) . British HIV Association guidelines for HIV-associated malignancies 2008 . HIV MED vol. 9 , ( 6 ) 336 - 388 .

Perry J, Nsubuga E, Joel S, Shamash J, El-Hariry I, Powles T ( 2008 ) . A synergistic interaction between lapatinib and topoisomerase I inhibitors in cisplatin sensitive and resistant cancer cell lines . JOURNAL OF CLINICAL ONCOLOGY vol. 26 , ( 15 )

Gerlinger M, Wilson P, Powles T, Shamash J ( 2008 ) . Non-castrate status at the end of chemotherapy for metastatic hormone-resistant prostate cancer (HRPC) correlates with a better overall survival . JOURNAL OF CLINICAL ONCOLOGY vol. 26 , ( 15 )

Bower M, Stebbing J, Tuthill MH, Krell J, Campbell V, Nelson M, Gazzard B, Powles T ( 2008 ) . Recovery of cellular immunity following chemotherapy for AIDS related non Hodgkin's lymphoma . JOURNAL OF CLINICAL ONCOLOGY vol. 26 , ( 15 )

Bazeos A, Powles T, Stebbing J, Mandalia S, Bower M ( 2008 ) . The increasing incidence of HIV-associated multicentric Castlemans disease . JOURNAL OF CLINICAL ONCOLOGY vol. 26 , ( 15 )

Stebbing J, Powles T, Mandalia S, Nelson M, Gazzard B, Bower M ( 2008 ) . Use of antidepressants and risk of cancer in individuals infected with HIV . J CLIN ONCOL vol. 26 , ( 14 ) 2305 - 2310 .

Bower M, Stebbing J, Tuthill M, Campbell V, Krell J, Holmes P, Ozzard A, Nelson M et al. ( 2008 ) . Immunologic recovery in survivors following chemotherapy for AIDS-related non-Hodgkin lymphoma . BLOOD vol. 111 , ( 8 ) 3986 - 3990 .

Sonpavde G, Ross R, Powles T, Sweeney CJ, Hahn N, Hutson TE, Galsky MD, Lerner SP et al. ( 2008 ) . Novel agents for muscle-invasive and advanced urothelial cancer . BJU INT vol. 101 , ( 8 ) 937 - 943 .

Macdonald DC, Nelson M, Bower M, Powles T ( 2008 ) . Hepatocellular carcinoma, human immunodeficiency virus and viral hepatitis in the HAART era . WORLD J GASTROENTERO vol. 14 , ( 11 ) 1657 - 1663 .

Krege S, Beyer J, Souchon R, Albers P, Albrecht W, Algaba F, Bamberg M, Bodrogi I et al. ( 2008 ) . European consensus conference on diagnosis and treatment of germ cell cancer: A report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): Part I . EUR UROL vol. 53 , ( 3 ) 478 - 496 .

Krege S, Beyer J, Souchon R, Albers P, Albrecht W, Alyaba F, Bamberg M, Bodrogi I et al. ( 2008 ) . European consensus conference on diagnosis and treatment of germ cell cancer: A report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): Part II . EUR UROL vol. 53 , ( 3 ) 497 - 513 .

Powles T, Robinson D, Shamash J, Moller H, Tranter N, Oliver T ( 2008 ) . The long-term risks of adjuvant carboplatin treatment for stage I seminoma of the testis . ANN ONCOL vol. 19 , ( 3 ) 443 - 447 .

Stebbing J, Powles T, Bower M ( 2008 ) . AIDS-associated Kaposi's sarcoma associated with a low viral load and a high CD4 cell count . AIDS vol. 22 , ( 4 ) 551 - 552 .

Shamash J, Davies A, Ansell W, Mcfaul S, Wilson P, Oliver T, Powles T ( 2008 ) . A phase II study investigating the re-induction of endocrine sensitivity following chemotherapy in androgen-independent prostate cancer . BRIT J CANCER vol. 98 , ( 1 ) 22 - 24 .

Krege S, Beyer J, Souchon R, Albers P, Albrecht W, Algaba F, Bamberg M, Bodrogi I et al. ( 2008 ) . Corrigendum to: "European Consensus Conference on Diagnosis and Treatment of Germ Cell Cancer . European Urology vol. 54 , ( 2 )

Liu WM, Scott KA, Shamash J, Joel S, Powles TB ( 2008 ) . Enhancing the in vitro cytotoxic activity of Delta(9)-tetrahydrocannabinol in leukemic cells through a combinatorial approach . LEUKEMIA LYMPHOMA vol. 49 , ( 9 ) 1800 - 1809 .

Berney DM, Warren AY, Verma M, Kudahetti S, Robson JM, Williams MW, Neal DE, Powles T et al. ( 2008 ) . Malignant germ cell tumours in the elderly: a histopathological review of 50 cases in men aged 60 years or over . Mod Pathol vol. 21 , ( 1 ) 54 - 59 .

Waters L, Nelson M, Mandalia S, Bower M, Powles T, Gazzard B, Stebbing J ( 2008 ) . The risks and incidence of K65R and L74V mutations and subsequent virologic responses . CLIN INFECT DIS vol. 46 , ( 1 ) 96 - 100 .

Bower M, Powles T, Williams S, Davis TN, Atkins M, Montoto S, Orkin C, Webb A et al. ( 2007 ) . Brief communication: rituximab in HIV-associated multicentric Castleman disease . Ann Intern Med vol. 147 , ( 12 ) 836 - 839 .

Sonpavde G, Chi KN, Powles T, Sweeney CJ, Hahn N, Hutson TE, Galsky MD, Berry WR et al. ( 2007 ) . Neoadjuvant therapy followed by prostatectomy for clinically localized prostate cancer . Cancer vol. 110 , ( 12 ) 2628 - 2639 .

Powles T, Stebbing J, Montoto S, Nelson M, Gazzard B, Orkin C, Webb A, Bower M ( 2007 ) . Rituximab as retreatment for rituximab pretreated HIV-associated multicentric Castleman disease [4] . Blood vol. 110 , ( 12 ) 4132 - 4133 .

Davies CL, Chinn R, Nelson M, Rasanesan M, Gazzard B, Powles T, Bower M, Stebbing J ( 2007 ) . Outcome in AIDS-related systemic non-Hodgkin lymphoma and leptomeningeal disease is not predicted by a CT brain scan . AM J NEURORADIOL vol. 28 , ( 10 ) 1988 - 1990 .

Shamash J, Stebbing J, Powles T ( 2007 ) . Germ-cell tumors . NEW ENGL J MED vol. 357 , ( 17 ) 1771 - 1772 .

Shamash J, Powles T, Ansell W, Berney D, Stebbing J, Mutsvangwa K, Wilson P, Asterling S et al. ( 2007 ) . Erratum: GAMEC - A new intensive protocol for untreated poor prognosis and relapsed or refractory germ cell tumours (British Journal of Cancer (2007) 97, (308-314) DOI: 10.1038/6603865) . British Journal of Cancer vol. 97 , ( 8 )

Young AM, Powles T, Holmes P, Wang J, Nelson M, Anderson J, Bower MD, Brock CS ( 2007 ) . An HIV-associated mediastinal germ cell tumour complicated by acute myeloid leukaemia . Journal of HIV Therapy vol. 12 , ( 3 ) 68 - 71 .

Bazeos A, Powles T, Stebbing J ( 2007 ) . HIV-associated multicentric Castleman's disease: From case reports to evidence . Journal of HIV Therapy vol. 12 , ( 3 ) 61 - 62 .

Walters Z, Shamash J, Powles T ( 2007 ) . Prostate cancer in HIV-positive individuals: what we know and what we don't . J HIV Ther vol. 12 , ( 3 ) 66 - 67 .

Stebbing J, Nathan B, Jones R, McKenna A, Powles T, Bower M, Holmes P, Gazzard B et al. ( 2007 ) . Virological failure and subsequent resistance profiles in individuals exposed to atazanavir . AIDS vol. 21 , ( 13 ) 1826 - 1828 .

Shamash J, Powles T, Ansell W, Stebbing J, Mutsvangwa K, Wilson P, Asterling S, Liu S et al. ( 2007 ) . GAMEC - a new intensive protocol for untreated poor prognosis and relapsed or refractory germ cell tumours . BRIT J CANCER vol. 97 , ( 3 ) 308 - 314 .

Powles T, Murray I, Brock C, Oliver T, Avril N ( 2007 ) . Molecular positron emission tomography and PET/CT imaging in urological malignancies . Eur Urol vol. 51 , ( 6 ) 1511 - 1520 .

Stebbing J, Sanitt A, Teague A, Powles T, Nelson M, Gazzard B, Bower M ( 2007 ) . Prognostic significance of immune subset measurement in individuals with AIDS-associated Kaposi's sarcoma . J CLIN ONCOL vol. 25 , ( 16 ) 2230 - 2235 .

Shamash J, Powles T, Mutsvangwa K, Wilson P, Ansell W, Walsh E, Berney D, Stebbing J et al. ( 2007 ) . A phase II study using a topoisomerase I-based approach in patients with multiply relapsed germ-cell tumours . ANN ONCOL vol. 18 , ( 5 ) 925 - 930 .

Powles T, Ell PJ ( 2007 ) . Does PET imaging have a role in renal cancers after all? . LANCET ONCOL vol. 8 , ( 4 ) 279 - 281 .

Stebbing J, Powles T ( 2007 ) . Stress in the workplace amongst medical professionals . J POSTGRAD MED vol. 53 , ( 2 ) 83 - 84 .

Powles T, Savage PM, Stebbing J, Short D, Young A, Bower M, Pappin C, Schmid P et al. ( 2007 ) . A comparison of patients with relapsed and chemo-refractory gestational trophoblastic neoplasia . BRIT J CANCER vol. 96 , ( 5 ) 732 - 737 .

Powles T, Perry J, Shamash J, Liu W, Oliver T, Joel S ( 2007 ) . A comparison of the platinum analogues in bladder cancer cell lines . UROL INT vol. 79 , ( 1 ) 67 - 72 .

Powles T, Young A, Sanitt A, Stebbing J, Short D, Bower M, Savage PM, Seckl MJ et al. ( 2006 ) . Erratum: The significance of the time interval between antecedent pregnancy and diagnosis of high-risk gestational trophoblastic tumours (British Journal of Cancer (2006) 95, (1145-1147) DOI: 10.1038/sj.bjc.6603416) . British Journal of Cancer vol. 95 , ( 12 )

Powles T, Young A, Sanitt A, Stebbing J, Short D, Bower M, Savage PM, Seckl MJ et al. ( 2006 ) . The significance of the time interval between antecedent pregnancy and diagnosis of high-risk gestational trophoblastic tumours . Br J Cancer vol. 95 , ( 9 ) 1145 - 1147 .

Powles T, Macdonald D, Nelson M, Stebbing J ( 2006 ) . Hepatocellular cancer in HIV-infected individuals: tomorrow's problem? . EXPERT REV ANTICANC vol. 6 , ( 11 ) 1553 - 1558 .

Powles T, Oliver T, Bower M ( 2006 ) . Non-AIDS-defining cancers in people with HIV infection: a sleeping giant? . J HIV Ther vol. 11 , ( 3 ) 57 - 60 .

Stebbing J, Powles T, Nelson M, Bower M ( 2006 ) . Significance of variation within HIV, EBV, and KSHV subtypes . Journal of the International Association of Physicians in AIDS Care vol. 5 , ( 3 ) 93 - 102 .

Bower M, Powles T, Nelson M, Mandalia S, Gazzard B, Stebbing J ( 2006 ) . Highly active antiretroviral therapy and human immunodeficiency virus - Associated primary cerebral lymphoma . Journal of the National Cancer Institute vol. 98 , ( 15 ) 1088 - 1091 .

Powles T, Young A, Short D, Savage P, Pappin C, Schmid P, Seckl M ( 2006 ) . The outcome of patients with relapsed gestational trophoblastic neoplasm (GTN) after the completion of chemotherapy . JOURNAL OF CLINICAL ONCOLOGY . vol. 24 , 263S - 263S .

Stebbing J, Sanitt A, Nelson M, Powles T, Gazzard B, Bower M ( 2006 ) . A prognostic index for AIDS-associated Kaposi's sarcoma in the era of highly active antiretroviral therapy . Lancet vol. 367 , ( 9521 ) 1495 - 1502 .

Liu WM, Powles TB ( 2006 ) . Cannabinoids: Do they have a role in cancer therapy? . LETT DRUG DES DISCOV vol. 3 , ( 2 ) 76 - 82 .

Powles T, Savage P, Short D, Young A, Pappin C, Seckl MJ ( 2006 ) . Residual lung lesions after completion of chemotherapy for gestational trophoblastic neoplasia: should we operate? . BRIT J CANCER vol. 94 , ( 1 ) 51 - 54 .

Liu WM, Baird R, Sarker D, Powles T ( 2005 ) . Antiapoptotic effect of growth factors in leukemia [1] . Journal of Clinical Oncology vol. 23 , ( 3 )

Bhardwa JM, Powles T, Berney D, Baithun S, Nargund VH, Oliver RTD ( 2005 ) . Assessing the size and stage of testicular germ cell tumours: 1984-2003 . BJU Int vol. 96 , ( 6 ) 819 - 821 .

Waterston AM, Gumbrell L, Bratt T, Waller S, Gustav-Aspland J, L'Hermenier C, Bellenger K, Campbell M et al. ( 2005 ) . Phase I study of TNFα AutoVaccine in Patients with metastatic cancer . Cancer Immunology, Immunotherapy vol. 54 , ( 9 ) 848 - 857 .

Bower M, Gazzard B, Mandalia S, Newsom-Davis T, Thirlwell C, Dhillon T, Young AM, Powles T et al. ( 2005 ) . A prognostic index for systemic AIDS-related non-Hodgkin lymphoma treated in the era of highly active antiretroviral therapy . Annals of Internal Medicine vol. 143 , ( 4 )

Shamash J, Powles T, Mutsangwa K, Cotton L, Oliver T ( 2005 ) . A phase II study of irinotecan, paclitaxel and oxaliplatin (IPO) in patients with multiply relapsed germ cell tumours (GCT) . JOURNAL OF CLINICAL ONCOLOGY . vol. 23 , 384S - 384S .

Powles TB, Bhardwa J, Shamash J, Mandalia S, Oliver T ( 2005 ) . The changing presentation of germ cell tumours of the testis between 1983 and 2002 . BJU INT vol. 95 , ( 9 ) 1197 - 1200 .

Berney DM, Argyle K, Cheang M, Powles T, Oliver RTD ( 2005 ) . Erythropoietin and erythropoietin receptor expression in renal cell carcinomas . JOURNAL OF PATHOLOGY . vol. 205 , 14 - 14 .

Bower M, Powles T, Stebbing J, Thirlwell C ( 2005 ) . Potential antiretroviral drug interactions with cyclophosphamide, doxorubicin, and etoposide [10] . Journal of Clinical Oncology vol. 23 , ( 6 ) 1328 - 1329 .

Shamash J, Powles T, Wilson P, Ansell W, Oliver T ( 2005 ) . Prognostic factors in cytokine-refractory renal cell carcinoma treated with irinotecan, cisplatin, and mitomycin chemotherapy . J CLIN ONCOL vol. 23 , ( 6 ) 1323 - 1325 .

Powles T, te Poele R, Shamash J, Chaplin T, Propper D, Joel S, Oliver T, Liu WM ( 2005 ) . Cannabis-induced cytotoxicity in leukemic cell lines: the role of the cannabinoid receptors and the MAPK pathway . Blood vol. 105 , ( 3 ) 1214 - 1221 .

Bower M, Powles T, Newsom-Davis T, Thirlwell C, Stebbing J, Mandalia S, Nelson M, Gazzard B ( 2004 ) . HIV-associated anal cancer: Has highly active antiretroviral therapy reduced the incidence or improved the outcome? . Journal of Acquired Immune Deficiency Syndromes vol. 37 , ( 5 ) 1563 - 1565 .

Marvin V, Stebbing J, Powles T, Bower M ( 2004 ) . The pharmacogenomics of anti-cancer chemotherapy . Minerva Biotecnologica vol. 16 , ( 3 ) 181 - 188 .

Oliver T, Shamash J, Powles T, Somasundram U ( 2004 ) . 20 year phase 1/2 study of single agent carboplatin in metastatic seminoma: Could it have been accelerated by 72 hr PET scan response? . JOURNAL OF CLINICAL ONCOLOGY . vol. 22 , 447S - 447S .

Powles T, Shamash J, Ong J, MacDonald D, Kyle F, Palmiera C, Moller H, Oliver T ( 2004 ) . The rising incidence of stage I seminoma; a reflection of earlier diagnosis of germ cell cancer of the testis in last 20 years . JOURNAL OF CLINICAL ONCOLOGY . vol. 22 , 387S - 387S .

Powles T, Bower M, Shamash J, Stebbing J, Ong J, Daugaard G, De Ruiter A, Johnson M et al. ( 2004 ) . Outcome of patients with HIV-related germ cell tumours: a case-control study . BRIT J CANCER vol. 90 , ( 8 ) 1526 - 1530 .

Powles T, Powles J, Nelson M, Sandison A, Peston D, Buchannan J, Mandalia S, Gazzard B et al. ( 2004 ) . Head and neck cancer in patients with human immunodeficiency virus-1 infection: incidence, outcome and association with Epstein-Barr virus . J LARYNGOL OTOL vol. 118 , ( 3 ) 207 - 212 .

Liu WM, Powles T, Shamash J, Propper D, Oliver T, Joel S ( 2004 ) . Effect of haemopoietic growth factors on cancer cell lines and their role in chemosensitivity . Oncogene vol. 23 , ( 4 ) 981 - 990 .

Powles T, Shamash J, Liu W ( 2004 ) . Erythropoietin to treat anaemia in patients with head and neck cancer . LANCET vol. 363 , ( 9402 ) 82 - 82 .

Kaanders JHAM, Van Der Kogel AJ, Haddad R, Posner M, Leyland-Jones B, Mahmud S, Blumberg N, Heal JM et al. ( 2004 ) . Erythropoietin to treat anaemia in patients with head and neck cancer [2] (multiple letters) . Lancet vol. 363 , ( 9402 ) 78 - 79 .

Powles T, Bower M ( 2004 ) . HIV and the risk of lung cancer . Journal of Clinical Oncology vol. 22 , ( 7 ) 1348 - 1349 .

Stebbing J, Wildfire A, Portsmouth S, Powles T, Thirlwell C, Hewitt P, Nelson M, Patterson S et al. ( 2003 ) . Paclitaxel for anthracycline-resistant AIDS-related Kaposi's sarcoma: Clinical and angiogenic correlations . Annals of Oncology vol. 14 , ( 11 ) 1660 - 1666 .

Powles T, Nelson M, Bower M ( 2003 ) . HIV-related lung cancer - A growing concern? . International Journal of STD and AIDS vol. 14 , ( 10 ) 647 - 651 .

Powles T, Shamash J, Berney D, Oliver RTD ( 2003 ) . Irinotecan in patients with relapsed or cisplatin-refractory germ cell cancer: a phase II study of the German Testicular Cancer Study Group . BRIT J CANCER vol. 89 , ( 6 ) 1140 - 1141 .

Powles T, Thirwell C, Newsom-Davis T, Nelson M, Shah P, Cox S, Gazzard B, Bower M ( 2003 ) . Does HIV adversely influence the outcome in advanced non-small-cell lung cancer in the era of HAART? . British Journal of Cancer vol. 89 , ( 3 ) 457 - 459 .

Powles T, Thirlwell C, Nelson M, Bower M ( 2003 ) . Immune reconstitution inflammatory syndrome mimicking relapse of AIDS related lymphoma in patients with HIV 1 infection . Leukemia and Lymphoma vol. 44 , ( 8 ) 1417 - 1419 .

Powles T, Liu W, Shamash J, Oliver T, Joel S ( 2003 ) . The effect of recombinant erythropoeitin on renal cancer cell lines and its role in chemosensitivity . BRITISH JOURNAL OF CANCER . vol. 88 , S66 - S66 .

Powles T, Shamash J, Joel S, Oliver T, Liu W ( 2003 ) . The role of CB1 and CB2 receptors in cannabis induced apoptosis in vitro . BRITISH JOURNAL OF CANCER . vol. 88 , S25 - S25 .

Powles T, Bower M, Daugaard G, Shamash J, De Ruiter A, Johnson M, Fisher M, Anderson J et al. ( 2003 ) . Multicenter study of human immunodeficiency virus-related germ cell tumors . J CLIN ONCOL vol. 21 , ( 10 ) 1922 - 1927 .

Bower M, Powles T, Nelson M, Shah P, Cox S, Mandelia S, Gazzard B ( 2003 ) . HIV-related lung cancer in the era of highly active antiretroviral therapy . AIDS vol. 17 , ( 3 ) 371 - 375 .

Cuzick J, Powles T, Veronesi U, Forbes J, Edwards R, Ashley S, Boyle P ( 2003 ) . Overview of the main outcomes in breast-cancer prevention trials . Lancet vol. 361 , ( 9354 ) 296 - 300 .

Powles T, Nelson M, Bower M ( 2003 ) . HIV-related testicular cancer . International Journal of STD and AIDS vol. 14 , ( 1 ) 24 - 27 .

Powles T, Daugaard G, Nelson M, Oliver T, Fisher M, Stebbing J, Johnson M, Gazzard B et al. ( 2002 ) . Multi-centre cohort study of testicular, cancer in men with HIV . BRIT J CANCER vol. 86 , S19 - S19 .

Powles T, Imami N, Nelson M, Gazzard BG, Bower M ( 2002 ) . Effects of combination chemotherapy and highly active antiretroviral therapy on immune parameters in HIV-1 associated lymphoma . AIDS vol. 16 , ( 4 ) 531 - 536 .

Powles T, Bower M, Nelson M, Oliver RTD ( 2002 ) . HIV related testicular cancer . GERM CELL TUMOURS V . Editors: Harden, P, Joffe, JK, Jones, WG , 51 - 52 .

Powles T, Matthews G, Bower M ( 2000 ) . AIDS related systemic non-Hodgkin's lymphoma . Sexually Transmitted Infections vol. 76 , ( 5 ) 335 - 341 .

Matthews GV, Bower M, Mandalia S, Powles T, Nelson MR, Gazzard BG ( 2000 ) . Changes in acquired immunodeficiency syndrome-related lymphoma since the introduction of highly active antiretroviral therapy . Blood vol. 96 , ( 8 ) 2730 - 2734 .

Powles T, Bower M ( 2000 ) . HIV-associated Hodgkin's disease . International Journal of STD and AIDS vol. 11 , ( 8 ) 492 - 494 .

Gill J, Powles T, Bower M ( 2000 ) . The molecular genetics of human herpesvirus 8 . Hospital Medicine vol. 61 , ( 5 ) 306 - 309 .